



REVIEW ARTICLE

Open Access



The role of gut microbiota in human metabolism and inflammatory diseases: a focus on elderly individuals

Mansoor Khaledi^{1,2}, Behnam Poureslamfar³, Hashem O. Alsaab⁴, Shahrad Tafaghodi⁵, Ahmed HJazi⁶, Rajesh Singh⁷, Ahmed Hussien Alawadi⁸, Ali Alsaalamy⁹, Qutaiba A. Qasim¹⁰ and Fatemeh Sameni^{1*}

Abstract

Background The gut microbiota plays a crucial role in regulating the host's immune responses during aging, which was characterized by a different abundance of bacteria in several age groups.

Main body Gut microbiota dysbiosis is associated with aging, antibiotic exposure, underlying diseases, infections, hormonal variations, circadian rhythm, and malnutrition, either singularly or in combination. The appropriate use of prebiotics and probiotics may be able to prevent or reduce this disruption.

Conclusion The current review focuses on the gut microbiota composition across the life cycle, factors affecting gut microbiota changes with aging, and interventions to modulate gut microbiota.

Keywords Gut microbiota, Aging, Inflammatory disease, Metabolism, Probiotic

*Correspondence:

Fatemeh Sameni
university.ac66@gmail.com

¹ Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran

² Department of Microbiology and Immunology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

³ Department of Biology, Faculty of Science, Yasouj University, Yasouj, Iran

⁴ Department of Pharmaceutics and Pharmaceutical Technology, Taif University, 21944 Taif, Saudi Arabia

⁵ Department of Clinical Biochemistry, School of pharmacy and Pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, Iran

⁶ Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, 11942 Al-Kharj, Saudi Arabia

⁷ Department of Electronics & Communication Engineering, Uttarakhand Institute of Technology, Uttarakhand University, Dehradun 248007, India

⁸ College of technical engineering, the Islamic University, Najaf, Iraq

⁹ College of technical engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna 66002, Iraq

¹⁰ College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq

Introduction

Estimated to be 10 times more common than human host cells, commensal bacteria are found in billions in the human gastrointestinal system (Ramakrishna 2007). Known as “microbiota” the human body contains a wide variety of bacterial species and, to a lesser extent, viral and eukaryotic microorganisms. Since most microorganisms are found in the human gut, it can be referred to as an “organ of the microbiome.” The “gut microbiota” is the term used to refer to all gut bacteria together, whereas the “gut microbiome” refers to the genes that they are connected with (Sender et al. 2016). When one or more elements of the microbiota disappear, the microbiota profile is characterized by low diversity (Jeffery et al. 2016). Gut bacteria may mainly colonize hosts vertically, acquired from parents early in life and persisting after that. Alternatively, bacteria can also persist due to repeated recolonization of the host; persistence is possible through repeated reintroduction. Thus, dispersal strategies, bacterial transfer, and colonization of new environments may all contribute to persistence (Hildebrand et al. 2021).



The population of microbes known as the microbiota is not uniform. Instead, it is made up of a complex spectrum of microbial communities that interact with the host and one another in ways that have an impact on the health of the host (Clemente et al. 2012). The two primary phyla of bacteria are Bacteroidetes and Firmicutes, with several smaller subphyla, including Fusobacteria, Cyanobacteria, Proteobacteria, Verrucomicrobia, and Actinobacteria (Vemuri et al. 2018). The gut microbiota, which is regarded as an endocrine organ involved in preserving energy balance and host immunity, has recently been discovered to play a crucial role in the development of metabolic diseases (Clarke et al. 2014a, b). The gut microbiota mainly steady throughout adulthood, but as we age, disruptions emerge due to endogenous variables like cellular stress and external factors, including antibiotic consumption (Kohl et al. 2012). Major physiological changes brought on by aging include altered immune function, metabolism, and gut microbial composition (dysbiosis), which can result in a variety of gastrointestinal inflammatory diseases and autoimmune illnesses. Due to the disruption of gut homeostasis, there is immunosuppression and a low-grade inflammatory response (Franceschi 2007; Magrone and Jirillo 2013; Ostan et al. 2008).

A large variety of physiological, genetic, metabolic, and immunological systems are impacted by the complicated process of aging. This involves a weakened capacity to maintain a healthy, effective metabolic function as well as an immunological response. According to Alarcón and Rojo (2020), this illness is characterized by a gradual deterioration of cellular physiological functioning that impacts the immune system, causes inflammation, and metabolic problems, all of which are risk factors for developing other chronic diseases (Alarcón and Rojo 2020). Having access to health care for a longer period of time does not always imply living longer (WHO 2019). Frailty, which is described as “a condition of greater sensitivity to an inadequate resolution of homeostasis after a stressful event, which raises the likelihood of unfavorable consequences, including falls, delirium, and disability,” unfortunately frequently presents itself negatively as people age (Clegg et al. 2013). For elderly persons, in particular, the potential effects of gut microbiota on health are significant. This is due to the possibility that age-related alterations in innate immunity, sarcopenia, and cognitive function—all of which contribute to frailty—may be tempered by the microbiota. Independent investigations and cell culture-based research both demonstrate that the gut microbiota of older individuals varies from that of younger individuals. There is no age or time limit at which the profile of the microbiota abruptly changes. Changes happen instead gradually and

over time. More senior citizens desire or want the ability to live independently. Weakness is the main barrier to independent existence. Frailty does not result from chronological aging but from the accumulation of illnesses. The human gut microbiota is one “organ” that cannot be anticipated to follow a typical course of physiological decline. Although gut bacterial cells do not age on their own, aging may bring on disorders linked to the stomach and gut bacteria (O’Toole and Jeffery 2015). Centenarians have a microbiota that differs from that of the elderly (Biagi et al. 2010), consistent with the general trend of age-related microbiota. Lifestyle, especially diet, plays an important role, as aging is often associated with a decrease in the amount and variety of fiber-rich foods, and there is often a risk of malnutrition (Claesson et al. 2012). The homeostasis of numerous genetic, metabolic, and immunological systems may be preserved in order to slow down the aging process, according to recent research that has made significant strides in this area. Disturbances in the composition and function of the gut microbiome are intimately tied to several clinical concerns, including exposure to numerous medications and antibiotics, dietary changes, and constipation, which is frequently associated with age (Ivanov et al. 2008; Odamaki et al. 2016).

Gut microbiota composition across the life cycle

Maintaining the integrity of this superorganism is crucial for optimum health since 10^{13} human cells and 10^{14} common bacteria make up the physiological sequence of the gut microbiota throughout the human life cycle. Humans gradually develop a stable gut microbiota throughout an age-related physiological sequence that is impacted by both the host’s internal characteristics and outside stressors (Kim et al. 2011). The gut microbiota in people changes throughout time (Mateos et al. 2018). The process through which the microbiota changes over time due to host or ecological changes is known as “physiological succession” (Hamady et al. 2008). This dynamic gut microbial community expands quickly at birth (primary exposure), undergoes fast change before the age of three, notably during the weaning period (transition phase), stabilizes (stable phase), and then changes with aging (regression) occur (Ling et al. 2022). Understanding the precise pattern of gut microbiota growth throughout a person’s life provides insight into the function and processes of bacteria in host health and illness (Fig. 1).

Initial exposure

Long before the infant develops its unique microbiota, the gut is initially colonized. The primary determinant of the first microbial implantation is the maternal microbiome. Growing data supports the idea that during




Fig. 1 Overview of the development of gut microbiota

pregnancy, the mother’s microbiota is transferred to the fetus (Selma-Royo et al. 2021). Bacterial transmission across the placenta occurs naturally throughout development, and microbes present in the uterus may cause colonization in the growing fetus. These microbes interact well with the healthy maternal immune system, causing immunological tolerance and avoiding fetal rejection (Escobar et al. 2020). Along with intrauterine exposure, factors including the way a baby is born, the gestational age, the kind of feeding, the use of antibiotics, and the surroundings all have an impact on how the gut microbiota develops early (Ganal-Vonarburg et al. 2020; Vandenplas et al. 2020). It is acknowledged that one of the critical determinants of early colonization is the method of delivery. While the gut microbiota of babies delivered by cesarean delivery resembles the mother’s skin microbiota, that of normally born infants is comparable to their mothers’ vaginal and intestinal microbiota (Dominguez-Bello et al. 2010; Liu et al. 2019). In infants born through cesarean section, the development of the gut microbiota is postponed during the postpartum period, which in turn delays immune system maturation (Magne et al. 2017; Olszak et al. 2012). One of the most significant influences on the composition of the gut microbiota after delivery is the fetal age (C. J. Hill et al. 2017). Compared to their peers, preterm babies (those born at fewer than 37 weeks

of gestation) have a distinct microbiota composition. According to Hesla et al. (2014) research, preterm newborns exhibited significantly more Proteobacteria in their gut microbiota than infants of normal gestational age did in the first week (Hesla et al. 2014). According to Korpela et al. (2018), the microbiota develops after birth in four phases, with Staphylococcus, Enterococcus, Enterobacter, and ultimately Bifidobacterium dominating each stage. However, the Enterococcus phase was only seen in extremely preterm children and seems to be a rare occurrence. It appears that it postpones the succession of microorganisms. The sterile atmosphere of the neonatal intensive care unit, cesarean birth, mother and baby antibiotic exposure, and other difficulties specific to preterm newborns may affect the gut microbiota’s normal pattern of absorption (Ling et al. 2022). Mother-to-infant microbial transmission is restricted when mothers are exposed to antibiotics close to the time of delivery because this decreases the variety and richness of the maternal gut microbiota (M. Gibson et al. 2016). Greater than fetal age is the impact of antibiotic usage on the microbiome (Zhou et al. 2020). Compared to babies whose mothers got antibiotics, Arboleya et al. (2016) discovered that babies who did not get antibiotics had greater Firmicutes levels and lower Proteobacteria levels. The administration of perinatal antibiotics was hypothesized to be the cause

of the lower levels of Bifidobacterium and Bacteroidetes and the abundance of Clostridium and Lactobacillus in newborns delivered via cesarean section (Rutayisire et al. 2016), which is connected to the concurrent changes in the level of Short-chain fatty acid (SCFAs) (Arboleya et al. 2016). The influence of nutrition on gut colonization is another significant element. Due to its high concentration of special oligosaccharides, breast milk aids in the formation of a healthy microbiome in babies. The oligosaccharides and glycoproteins included in human milk can encourage the development of good microbes and inhibit harmful germs (Cong et al. 2016). Breast milk microbiome is the primary source of bacteria like Bifidobacterium, which has health advantages beyond nutrition (Benítez-Páez et al. 2020). These microbiota components may be vertically passed from mother to newborn during nursing. The bacterial makeup of breast milk is impacted by the stage of lactation, gestational age, birth method, mother food, and antibiotic exposure (Rogier et al. 2014). In addition to the aforementioned elements, the first colonization of the gut microbiota is also influenced by the surrounding environment, the length of hospitalization, birth weight, gender, genetic variables, race/ethnicity, maternal education, and maternal illnesses (Xu et al. 2020).

Transitional phase

Weaning causes the gut microbiota's composition to shift in a significant way. For newborns, the progressive switch from a diet high in milk to one that also contains other foods is a special and important event, but it may also be difficult on the host gut's physiology (Lallès et al. 2007). When solid food is introduced, the gut microbiota enters a new stage of growth marked by a sharp rise in bacterial population and evolution toward a makeup more resembling that of the adult microbiota (Subramanian et al. 2014). Proteobacteria and Actinobacteria are replaced as the main members of the newborn microbiota by Firmicutes and Bacteroidetes phyla due to the addition of dietary supplements and new nutrients during weaning (Fallani et al. 2011; Koenig et al. 2011). Consuming foods high in protein and fiber, such as meat, cheese, and Danish rye bread, is particularly linked to increased alpha diversity. Consuming more protein enriched the Lachnospiraceae family and decreased saccharolytic bacteria like those in the Bifidobacteraceae family, whereas increasing Prevotellaceae numbers was associated with higher fiber intake (Laursen et al. 2016). *Faecalibacterium prausnitzii* and *Akkermansia muciniphila* are absent or present in early infancy and reach adult levels by 12 months and 24 months, respectively (Yassour et al. 2016). In addition to having an impact on the variety and composition of the gut microbiota, the timing of supplemental feeding

(3 and 12 months) also has an impact on the concentration of SCFAs throughout the first year of life (Differding et al. 2020). The weaned group's fecal microbial population undergoes considerable alterations as a result of the consumption of an amylose corn starch diet, with Prevotella, Veillonella, and Collinsella levels linked with propionate synthesis significantly rising (Wang et al. 2019). The "weaning response," as it was dubbed by Nabhani et al. was discovered to be a potent immunological reaction brought on by the increasing microbiota at weaning. Inhibition of weaning causes pathological imprinting for increased susceptibility to colitis, allergic inflammation, and cancer later in life (Al Nabhani et al. 2019).

Stable phase

The human gut microbiota changes into adult composition 3 years after birth (Caporaso et al. 2011; Rajilić-Stojanović et al. 2009; Wu et al. 2011). Firmicutes and Bacteroidetes predominate in the stable, mature microbiota, characterized by increased bacterial diversity (Ho et al. 2018). In contrast to the first two phases, where Bifidobacterium predominated, the adult intestinal microbiota is dominated by Bacteroides and Eubacterium, which are referred to as the major microbiome. Although these genera may be a normal component of the intestinal bacterial community, Veillonella has been linked to various infections, and an abundance of intestinal bacteroids is linked to a higher body mass index in young children (Brook 1996; Lagier et al. 2012; Schwiertz et al. 2000; Vael et al. 2011). The adult-type gut microbiota may be categorized into three groups, or enterotypes, according to the primary microbiome: Bacteroides, Prevotella, and Ruminococcus (Costea et al. 2018; Manimozhiyan et al. 2011). Each of these three enterotypes, which are typically flexible, represents several stable states in the human gut microbiota. The gut microbiota can be disturbed by several diseases, including those brought on by probiotics, antibiotics, and dietary changes. A healthy microbiota must be maintained by homeostatic equilibrium among microbial communities and between microbes and the host gut interface. Our resistance to diseases linked to dysbiosis is facilitated by a robust microbiome (Ling et al. 2022). Beyond the capacity of the gut microbiota, the change from a main steady state to an alternate steady state can put the host in a pre-disease state and predispose them to chronic illnesses (Goyal et al. 2018). It implies that a critical factor in both health and disease is the flexibility of gut microbes (Sommer et al. 2017). By contrasting gut microbiomes and how they interact with tolerant and vulnerable hosts, omics research might find indicators of resilience. Increased gut microbiome flexibility can result in new disease prevention techniques by neutralizing or suppressing illness triggers, as well as

by finding and encouraging species and activities that are beneficial to health (Rosier et al. 2018). According to earlier studies, dietary interventions with significant compositional alterations can impact and modify the enterotype within 4 days (Kovatcheva-Datchary et al. 2015; Wu et al. 2011). Enterotypes, however, seem stable after around 10 days (Wu et al. 2011). According to Morrison et al. lowering soluble fiber can have an impact on the production of microbial metabolites that are crucial for controlling outcomes in the areas of metabolism, immunity, behavior, and neurobiology (Morrison et al. 2020).

Retrogression

The gut microbiota's makeup and activity are significantly influenced by aging. Less fiber consumption, ongoing home care, the use of antibiotics, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) may all be risk factors for these alterations (O'Toole and Jeffery 2015). As people get older, the microbiota in their intestines undergoes several changes, including a reduction in the variety of species present, an increase in the variation between people, an increase in the prevalence of proteobacteria, and a decrease in the prevalence of probiotic bacteria like Bifidobacterium. The breakdown of the intestinal mucosal barrier and a greater vulnerability to pathogen infection may be related to these alterations (Claesson et al. 2012; Lahtinen et al. 2009). The proportions of Firmicutes and Bacteroidetes have changed, one of the most significant microbiota traits in older adults. Younger persons have greater proportions of Firmicutes, whereas older adults have greater amounts of Bacteroidetes. As a result, one sign of aging is a decline in the Firmicutes/Bacteroidetes ratio (Mariat et al. 2009). Once someone enters long-term care, species linked with variety, such as Prevotella and allied taxa, see a dramatic drop in abundance (Claesson et al. 2012). Furthermore, recent studies have shown that aging is accompanied by changes in the dynamic network and an increase in the number of dominating species (Biagi et al. 2016; Rampelli et al. 2020). Elderly persons in excellent health have higher abundances or richer populations of some health-related groups in their gut microbiota, such as Christensenellaceae, Bifidobacterium, and Akkermansia (Biagi et al. 2016). Since they have achieved the pinnacles of life by avoiding, eliminating, or postponing chronic illnesses, centenarians serve as examples of healthy aging (Biagi et al. 2010). Chinese researchers (Luan et al. 2020) found that *Faecalibacterium prausnitzii*, a species with anti-inflammatory properties, was much more prevalent in centenarians' gut microbiota throughout the transition from health to death. In contrast to *Eubacterium limosum*'s more than tenfold growth, the microbiota of centenarians showed a considerable decline (Biagi et al.

2010). When compared to other age groups, centennial gut communities had much higher levels of *Akkermansia muciniphila*, a bacterium that is frequently used as an indication of a healthy gut community (Biagi et al. 2010). Two strains of Bacteroides, one strain of Ruminococcaceae, and one strain of Desulfovibrio were found to be associated with age and residency in healthy elderly Birmingham residents by a team of Chinese scientists (Zhao et al. 2011).

Gut microbiota and human metabolism

To provide energy for biological functions and growth, intestinal microbiota consumes food components (carbohydrates, proteins, and lipids) and host-derived components, such as expelled epithelial cells and mucus. These mechanisms produce metabolites that have an impact on human health and metabolism. SCFAs are produced as a result of carbohydrate fermentation and are used by the host (Ramakrishna and Roediger 1990). Protein fermentation generates phenolic compounds that might harm the host (Windey et al. 2012). These metabolites can be detoxified by the liver and the gut (Ramakrishna et al. 1989). Additionally, the gut bacteria produce several chemicals, including vitamin K and vitamin B compounds. It is doubtful that the host will be able to directly access vitamin B12, which is created by the gut flora. Because of the way vitamin B12 is metabolized, it must attach to factor R in the stomach, move to the intrinsic factor in the small intestine, and then be absorbed (Ramakrishna et al. 1989).

The gut microbiota and obesity

Studies in germ-free mice, who are typically thin, showed that the gut flora of normal mice increased body weight by more than 50% when they were given the transplanted flora (Bäckhed et al. 2004), demonstrating the importance of gut microbiota in the control of body weight. This is linked to an increase in the expression of genes from microorganisms that produce the enzymes necessary for the metabolism of SCFAs and the enzymatic breakdown of complex carbohydrates and sugars. Obese mice's intestinal microbiota exhibited a decline in bifidobacteria compared to wild-type mice's microbiota, along with the presence of Halomonas and Sphingomonas in the cecum, which likely plays a role in storing energy from carbohydrates that are not digested in the small intestine (Turnbaugh et al. 2006). Studies of human relationships worldwide show that obese persons have altered gut microbiotas compared to lean people, but the specific microbial communities affected by these alterations vary (Turnbaugh et al. 2009). There have been several attempts to clarify the nature of the connection between obesity and gut microbiota (Zsálíg et al. 2023). Many

microbial genes have been discovered to be shared by co-twins in studies of twin pairs matched for body mass index, indicating the existence of a core microbiome. Obese twins had bacteria and actinobacteria, but there were no appreciable alterations in the phylum Firmicutes, decreased microbial diversity, or alterations in the genes regulating metabolic pathways (Brand et al. 2021). Several microbial communities that are a part of the phylum Firmicutes are significant fermenters of carbohydrates and may aid in preserving energy from carbs. Microbial fermentation products influence energy metabolism and salvage through a number of neuroendocrine processes in addition to directly supplying energy in the form of SCFA (Canfora et al. 2017). By enhancing the oxidation of fatty acids in skeletal muscles and decreasing glycogen storage in the liver, this enzyme's activation may be necessary for germ-free mice to maintain their leanness (Li et al. 2022). In conclusion, the data we currently have pointed to the gut microbiota as being a significant factor in the emergence and maintenance of obesity. Their function might be influenced by how they interact with the genetic components of the host. Their enhanced ability to absorb energy from the large intestine by fermenting unabsorbed carbohydrates is one of the methods by which they cause obesity. Increased fatty acid uptake into fat cells and reduced fatty acid oxidation in skeletal muscle are the results of soluble substances released by the small intestine as a result of hormonal changes caused by SCFA nuclear receptors (Amorim et al. 2020). Additionally, increased intestinal permeability causes low-grade systemic inflammation in various organs, contributing to insulin resistance and its ensuing metabolic consequences (Ramakrishna 2013).

Gut microbiota and energy malnutrition

Intestinal mucosal inflammation may be linked to a lean body habit (Ramakrishna et al. 2006). In cases with tropical enteropathy, a subclinical inflammatory disease of the intestinal mucosa marked by lymphoplasmacytic inflammatory cell infiltration of the intestinal lamina propria, a lean body habitus may be present (Venkatraman et al. 2003). In animal models of overt colitis, changing the gut microbiota (by giving the animals certain microbial communities) reduces intestinal inflammation and increases body weight (Nanda Kumar et al. 2008). Studies on the gut microbiota and malnutrition are still in their infancy, and it is unclear how the two are related or whether changes in the gut microbiome are what cause malnutrition. Weight loss and a reduction in amino acid and carbohydrate metabolism were observed in gnotobiotic mice fed a Malawian diet and subsequently transplanted with the gut microbiota of Kwashiorkor children (Smith et al.

2013). That the gut microbiota has a role in the onset of malnutrition follows logically.

Gut microbiota and mineral absorption

Lactobacilli are substantially underrepresented in the gut microbiota of individuals with iron deficiency anemia, according to studies on patients with the condition. Lactobacilli need iron for significant development, thus those with low levels of iron may have less of it in their stomach (Scholz-Ahrens and Schrezenmeir 2002; Scholz-Ahrens and Schrezenmeir, 2007). Although the right colon and cecum also express enterocyte transporters involved in iron transport, the duodenum is still the predominant source of iron absorption (Levrat et al. 1991). A reasonable explanation for the connection between lactobacilli depletion and iron deficiency anemia is provided by the fact that lactobacilli are involved in the conversion of lactate to propionate in fermentation systems (Ramakrishna 2013).

Gut microbiota and glucose metabolism

There has been speculation regarding the significance of gut bacteria in the development of type 2 diabetes (T2D). Impairment of insulin signaling is caused by changes in the phosphorylation of the insulin receptor, insulin receptor substrate (IRS), and Akt, as well as alterations in the serine phosphorylation of the inhibitory IRS-1. It is connected to a notable rise in Firmicutes and a slight rise in Bacteroides (Munukka et al. 2012). Women with metabolic syndrome, a population linked to metabolic illness, have been found to have an increased frequency of *E. rectale/C. cocci* belonging to the Firmicutes group (Caricilli et al. 2011). In an intriguing randomized study, male recipients received intestinal injections of microbiota from lean donors (or the patient's microbiota as a control). Insulin sensitivity (glucose clearance rate) in receivers who received microbiota from lean donors dramatically enhanced 6 weeks after microbiota injection in patients with metabolic syndrome. This was linked to an increase in the number of butyrate-producing bacteria in feces (Tremaroli and Bäckhed 2012). However, it is still unknown exactly how the gut microbiota contributes to the development of diabetes and what mechanisms they may use to do so (Vrieze et al. 2012).

By having a nutritional impact and stimulating the production of GLP-2, butyrate fuels enterocytes and improves intestinal barrier performance (Cani et al. 2009). By encouraging preadipocyte and macrophage proliferation, upregulating ILC3, and boosting B and T lymphocyte infiltration, bacterial components in mouse metabolic tissue exacerbate inflammation. Proinflammatory cytokines associated with diabetes can aggravate

its consequences by reducing insulin signaling (Sanders et al. 2021).

Gut microbiota and lipid metabolism

The synthesis of bile salt hydrolases by some intestinal microbiota, particularly lactobacilli, allows them to hydrolyze bile salts. This disrupts the hepatic cycle of bile salt reabsorption, causing an increase in fecal bile salt loss and a subsequent drop in serum cholesterol as a result of diverting cholesterol synthesis to bile acid production (Favier et al. 1995; Levrat et al. 1994). Another way that the gut microbiota and dyslipidemia are related is through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A synthase by propionic acid, a substance that is produced by the gut bacteria. Reduced cholesterol synthesis is caused by liver activity (Y. Lin et al. 1995).

Reabsorbing fat and promoting lipid metabolism are benefits of the gut microbiota, which inhibits the inhibitory expression of lipoprotein lipase in adipose tissue cells. Sterol response element binding protein 1 (SREBP1), carbohydrate response element binding protein (ChREBP), and acetyl-CoA carboxylase 1 (ACC1) are among the genes that have increased in relation to the microbiota through lipid metabolism (Ilhan 2018) (Fig. 2).

Bacteroides thetaiotaomicron increases lipid hydrolysis by regulating the expression of cholesterol esterase (de Punder and Pruimboom 2015). Lipopolysaccharide

(LPS), the main component of Gram-negative bacteria’s cell wall, is elevated in plasma levels, and mucus integrity is weakened by high-fat diets. TLR-4 is involved in a process that transmits increased levels of LPS via intestinal capillaries. Impaired intestinal permeability raises blood levels of TNF- α , IL-1, IL-6, and plasminogen-1 activating inhibitor (PAI-1) and causes systemic inflammation with a significant accumulation of adipose in the liver. When short-chain fatty acids (SCFAs) produced by the microbiota activate AMPK, they reduce the production of fasting-induced adipose factor (FIAF), which increases the activity of LPS and inhibits the activity of PGC-1 α , the proximal proliferator-activated receptor co-activator. Most often, PPAR α is recognized as a metabolic regulator involved in energy storage that is expressed in the liver and brown adipose tissue. Lipogenesis improves control of beta-oxidation and fatty acid metabolism (Duszka et al. 2020) (Fig. 3).

The progression of metabolic disorders, such as diabetes and obesity, is subsequently accelerated by PPAR α suppression (Fluitman et al. 2017).

Propionate binds to both GPR41 and GPR43, butyrate to GPR41, and acetate to GPR43, among other SCFAs. Within the intestinal epithelium, GPR41 and GPR43 receptors are expressed (Sivaprakasam et al. 2016). PPARs are crucial mediators of adipogenesis, and SCFAs boost their expression. SCFAs induce adipose cells to produce leptin by attaching to GPR41. It is believed that




Fig. 2 Effect of the gut microbial community on fat metabolism and fat reabsorption




Fig. 3 Overview of the development of gut microbiota bacteroides thetaiotaomicron and its role in lipid metabolism and metabolic disorders

binding to GPR43 promotes adipogenesis. As a result, the fatty acid profile that results may be linked to the onset of obesity (Gomes et al. 2018). However, further research is required to validate these results in people.

Gut microbiota and protein metabolism

In a healthy state, nonabsorbable protein generated from the host is most likely the protein that travels to the large intestine and is subjected to microbial processing. Branch-chain amino acids, as well as a number of phenolic and other metabolites that may be hazardous to the host, are produced as a result of protein fermentation. These are mostly detoxified by the liver and intestinal wall. By supplying fermentable carbohydrates like lactulose to modify the fermentation profile to metabolites that do not influence cognition in the context of liver illness, where hepatic encephalopathy is mainly related to microbial metabolites of protein, this can be decreased. Recent research indicates that the makeup of the gut microbiome is related to cognition in people with liver disease (Davila et al. 2013; Nyangale et al. 2012). Compared to those without encephalopathy, cirrhotic patients with hepatic encephalopathy had higher levels of Veillonellaceae. A change in pathogenic microbiota in the stomach, or an increase in Alcaligenaceae and Porphyromonadaceae, was linked to cognitive impairments (Bajaj et al. 2012). Increased blood saturated and unsaturated microbial fatty acids and unsaturated microorganisms were the results of giving

rifaximin to cirrhotics with little hepatic encephalopathy (Bajaj et al. 2013). The gut microbiota undoubtedly supports the metabolic diseases linked to liver dysfunction, but their major involvement in the genesis of these instances is less plausible, while it is recognized, and will be the subject of research in the near future.

PPARs are crucial mediators of adipogenesis, and short-chain fatty acids (SCFAs) boost their expression. SCFAs induce adipose cells to produce leptin by attaching to GPR41. It is believed that binding to GPR43 promotes adipogenesis. As a result, the fatty acid profile that results may be linked to the onset of obesity (Davila et al. 2013). These bacterial metabolites impact epithelial physiology by regulating the signaling pathways of epithelial cells and modifying the host immune system (Blachier et al. 2007). Additionally, by modifying the expression of bacterial genes, these bacteria produce enzymes involved in the metabolism of amino acids (Bron et al. 2004). Numerous metabolites produced by the anaerobic breakdown of endogenous or undigested proteins in the colon are known to have hazardous qualities. It is commonly accepted that the presence of these metabolites, particularly from a high-protein diet, is linked to a range of inflammatory and chronic illnesses, including atherosclerosis, inflammatory bowel disease (IBD), and colon cancer, due to their detrimental effects on the host’s health (Windey et al. 2012). Laboratory experiments using isolated colonocytes or cell types have demonstrated that protein

fermentation byproducts such as NH₃ and H₂S can be hazardous to health (Leschelle et al. 2002).

The relationship between gut aging and inflammatory/autoimmune diseases

Numerous processes that could impact human function and the immune system may explain the link between gut microbiota imbalance and autoimmune disorders. For example, altering the host immune response and stimulating antigen-presenting cells (APCs), such as dendritic cells (DCs), can lead to the presentation of antigens and the release of cytokines, which in turn can affect T cell development and functionality. Additionally, this can diminish the action of T-regulating cells (Tregs) and Th17 cells, which are crucial for maintaining homeostasis. Antigen mimicry may cause exogenous and endogenous antigens to resemble each other, heightening autoimmunity through the activation of autoimmune T and B cells produced by pathogens. Moreover, variations in the intestinal mucosa's permeability due to the modulation of tight junction protein expression have been observed. Research suggests that in individuals with autoimmune illnesses, the gut microbiota may play a role in both the onset and aggravation of the condition (H. Xu et al. 2019). Among the potential mechanisms are antigenic mimicry, microbiota-induced host immune response, impact on intestinal mucosal permeability, and molecular mimicry (Cusick et al. 2012; English et al. 2023; Wildner 2023). Autoimmune illnesses have been related to changes in the populations of microbes in the gut. A possible contributing factor to autoimmune illnesses is the gut microbiota's ability to influence or impede the immune system's ability to distinguish between intrinsic and non-intrinsic stimuli. The immune system may become exposed to gut commensal bacteria in patients with autoimmune disorders, who often exhibit evidence of compromised gut barriers. In addition, immunological responses linked to the gut microbiota become aberrant and pathogenic when mucous immunity is not tolerated, which exacerbates the illness. There is growing scientific and clinical evidence that autoimmune illnesses may be more severe due to a persistent inflammatory response brought on by gut microbiome dysbiosis. Overall, in genetically predisposed people, the microbiota may either induce or prevent autoimmunity (H. Xu et al. 2019).

According to research using microbeless mice, TLR-2 impairment (TLR activation is dependent on the mice's microbiota state) causes a reduction in Treg-suppressing activity and Foxp3 expression, which in turn causes arthritis. TLR4 was also discovered to have a role in severe arthritis by regulating Th17 cell proliferation and IL-17 synthesis (Jiao et al. 2020). Additionally, Th17 growth and the synthesis of IL-1 β and IL-6 are aided by

the presence of segmented filamentous bacteria (SFB) in the gut. Thus, preserving homeostasis and averting RA and some other autoimmune disorders depends on a healthy balance in the TLR-mediated microbial differentiation of the gut. In mice lacking IL-1RA, arthritis developed on its own. Reduced IL-17 and IL-1 β secretion and increased TLR-2 and TLR-4 activation were seen in IL-1RA/GF mice, and these observations were linked to a weakening of RA (Abdollahi-Roodsaz et al. 2008; Rogier et al. 2015). After observing an increase in Th17 cells in the colon and the onset of severe arthritis, Maeda and colleagues transferred the intestinal microbiota from rheumatoid arthritis patients to SKG mice that were susceptible to arthritis but did not have germs. The researchers also noted an increase in IL-17 release when they cultured SKG dendritic cells with *Prevotella copri* in the presence of RA autoantigens. These findings suggest that the gut microbiota from RA causes autoreactive cells in the gut and increased joint inflammation (Maeda et al. 2016). Two autoantigens supporting the molecular mimicry process in RA include N-acetylglucosamine-6-sulfatase and filamine A, which have sequence homology with epiphones of gut microorganisms such as *Prevotella* spp (Bradley et al. 2017; Maeda and Takeda 2019) (Fig. 4).

On the other hand, Dysbiosis can be caused by both environmental changes and host genetic vulnerability (Harmsen and de Goffau 2016; Lee and Mazmanian 2010). A dysbiotic condition can cause changes in the relative abundance of particular microbial species, which can affect the integrity of the intestinal barrier and host immunological responses. Th1, Th2, and Th17 cells are frequently upregulated while Tregs and IgA are downregulated during dysregulated mucosal immune responses (Belkaid and Hand 2014; DeGruttola et al. 2016).

Inflammatory bowel disease (IBD)

IBD is a catch-all name for various intricate, long-term, inflammatory gastrointestinal illnesses (Mulder et al. 2014). IBD is connected to alterations in the gut microbiota and frequently manifests as Crohn's disease (CD) and ulcerative colitis (UC). However, it is uncertain if inflammation brought on by the disease or its etiology is to blame for these alterations. In contrast to healthy people, IBD patients have smaller microbiotas with less functional variety and stability. *Desulfovibrio desulfuricans*, *E. coli*, and Firmicutes from the *Clostridium leptum* group, especially *F. prausnitzii*, have been reported to be more common in the microbiome of IBD patients (Gevers et al. 2014; Martinez-Medina et al. 2009; Pascal et al. 2017). IBD patients often have 25% fewer microbial genes in their bodies than healthy individuals (Qin et al. 2010). Gut microbiome changes in inflammatory bowel disease patients




Fig. 4 The role of gut microbiota imbalance in autoimmune disorders: mechanisms and implications

are linked to shifts in the populations of bacteria that have a role in either dampening or increasing inflammation. Low levels of *F. prausnitzii*, a SCFA-producing bacterium that promotes gut health by increasing Tregs and anti-inflammatory cytokines, are found in people with CD (Sokol et al. 2008; Willing et al. 2009). Having less *F. prausnitzii* bacteria in the body is linked to a higher risk of CD relapse after surgery in people (Sokol et al. 2008). Increased generation of hydrogen sulfate has also been linked to an increase in the prevalence of

sulfate-reducing bacteria such desulfuricans in people with IBD, which can damage IECs and lead to mucosal inflammation (Jia et al. 2012; Loubinoux et al. 2002). CD patients have been shown in multiple human investigations to have elevated levels of *E. coli* that live in the mucosa (Darfeuille-Michaud et al. 2004; Martinez-Medina et al. 2009), causing the gut lining to become more permeable and inflammatory (Palmela et al. 2018). Reduced tryptophan levels have been linked to IBD in humans and mice (Lamas et al. 2016; Nikolaus et al. 2017). Disease severity and IL-22 production are

inversely associated with serum tryptophan levels in inflammatory bowel disease patients (Nikolaus et al. 2017).

IBD patients frequently have stronger T cell and antibody responses to microbial antigens (Britton et al. 2020; Moayyedi et al. 2015). The coexistence of gut microbiota and T-cell differentiation subgroups in the immune response may influence the development of inflammatory bowel disease (IBD) (Qiu et al. 2022). Though Th cell-driven inflammation defends the body against dangerous infections, intestinal inflammation is linked to an overabundance of Th cell activation. The prevailing consensus is that Th1 cells and Th17 cell activation play a major role in Crohn's disease (CD) occurrence, whereas the interaction between Th1 and Th2 cells results in ulcerative colitis (UC) occurrence (Lopetuso et al. 2018). Further research has revealed a stronger correlation between Th17 cell activity and the incidence of inflammatory bowel disease (IBD). IL-17 and IL-22, the two primary cytokines released by Th17 cells, are essential mediators of immunological damage and autoimmune disorders. In cases of acute colitis, IL-22 is thought to have a protective effect. However, research has also revealed that IL-22 and IL17A work together to mediate pathogenicity in chronic colitis (Powell et al. 2020).

Th17 cells are generated by necrotic intestinal mucosal cells, which stimulate macrophages to produce IL-6 and TGF- β via the activity of STAT3 and retinoid-related orphan receptor gamma (ROR γ t) (Owaga et al. 2015). Effective T cells have the ability to cause an exaggerated immune response in the gut, which might ultimately result in harm to the intestinal mucosa due to the immunosuppressive control of Treg cells (Sun et al. 2017). In a typical setting, Th17 and Tregs are in balance. The Th17/Tregs balance is upset when there is an overabundance of Th17 and a reduction in Treg cells. The gut mucosa may sustain harm as a result of this imbalance. T cells can be stimulated to develop into Th17 cells by IL-6 and modest doses of TGF- β . Excessive TGF- β can promote the growth of Treg cells while suppressing the generation of Th17 cells. Additionally, Th17 cells can inhibit Treg cell multiplication. In peripheral blood, patients with inflammatory bowel disease (IBD) exhibited lower Treg counts and higher Th17 counts, suggesting a major role for the Th17/Treg imbalance in the onset and maintenance of IBD. Furthermore, Th17 and Treg phenotypes in T cells can be induced by the gut microbiota through changes in the intestinal environment. Colonized segmented filamentous bacteria (SFB) in the small intestine of mice can cause inflammation in the gut by stimulating Th17 cells in the intestinal lamina propria to produce IL-17 and IL-22 (L. Lin and Zhang 2017). On the other hand, Treg cells, which have anti-inflammatory properties, can also

be increased by gut bacteria. In inflammatory bowel disease (IBD), *Bacteroides thetaiotaomicron* summarizes the impact of gut microbiota and compels Tregs to modify the immune system (Hoffmann et al. 2016).

Human blood and colon mucosa have been shown to include circulating T cells CD4 and CD8 α (DP8 α), as well as *Faecalibacterium prausnitzii*, which have characteristics similar to Treg cells (Godefroy et al. 2018). Inadequate colonization of *Klebsiella pneumoniae* in the gut shows a distinct method for generating colitis but does not enhance the generation of regulatory T cells or anti-inflammatory T cells. Instead, it preferentially enhances Th1 induction (Atarashi et al. 2017). IBD is primarily caused by gut microbiota dysbiosis, cytokine imbalances, and mucosal barrier deterioration, which all work together to induce mucosal inflammation.

Rheumatoid arthritis (RA)

Approximately 0.5–1 percent of people worldwide suffer from RA, a systemic autoimmune condition that causes joint damage (Silman and Pearson 2002). Reduced gut microbial diversity is seen in RA patients, and their guts have dysbiosis, which is marked by an excess of *Prevotella*, *Lactobacilli*, and *Collinsella* (Chen et al. 2016; Liu et al. 2013; Maeda et al. 2016). Inducing a Th17 response, which in turn causes B-cell differentiation, the creation of autoantibodies, and an increase in intestinal permeability, is what *Prevotella* and *Collinsella* can do in mouse models, according to those studies (Chen et al. 2016). The inflammation associated with RA is believed to be caused by these autoantibodies, which attack the joints.

Multiple sclerosis (MS)

The CNS and microbiota are interdependent in MS (Mahajan et al. 2021). Because the CNS contains peptides that can modify food absorption and physiological processes governing nutrient absorption, such as neuropeptide Y and the peptide linked with the melanocortin antagonist agouti-related peptide, it has an impact on the composition of the gut microbiota. The gut microbiota secretes LPS, polysaccharide A, and SCFAs that can alter brain activity (Wang and Kasper 2014). The animal model of autoimmune encephalomyelitis for multiple sclerosis has shown that colonization of segmented filamentous bacteria (SFB) increases the number of Th17 cells in the propria and CNS layers, thereby exacerbating the severity of the disease (Ochoa-Repáraz and Kasper 2014). The production of microbiota-derived butyrate by Firmicutes and *Butyricimonas* decreased, but *Methanobrevibacter smithii* was more prevalent in untreated MS patients (Jhangi et al. 2014). Because they cause Treg cells to proliferate in the gut, *Butyricimonas* spp., a type of bacterium that produces butyrate, modulates immunity.

Patients with active MS frequently have decreased species richness, greater abundance of Anaerostipae, Faecalibacteria, and Pseudomonas, as well as lower concentrations of Bacteroides, Prevotella, Parabacteroides, and Adlercreutzia. However, a typical MS microbiome phenotype has not yet been discovered (Cantarel et al. 2015; Chen et al. 2016). Reduced levels of IL-17 in the gut and central nervous system, as well as an increase in peripheral Tregs, were seen in a GF mouse model of autoimmune encephalomyelitis (EAE), which is also a model for MS (Lee et al. 2011). Additionally, decreased submucosa thickness, altered tight junctions expression in IEC, and altered intestinal permeability are strongly associated with disease severity in EAE models (Nouri et al. 2014; Secher et al. 2017).

Factors affecting gut microbiota changes with aging

Following a study of the relevant academic research, it can be assumed that some of the most important variables that can influence the composition and general health of the human gut microbiota include genetics, geographic environment, food, exercise, illness, and concurrent medicines. In the following subsections, these aspects are thoroughly evaluated regarding their impact and mode of operation.

Genetic background and environmental factors

The crucial role of genetics in modulation was discovered based on prior research on twins and first-degree relatives, as well as the observation that family members share a microbiota that is more similar than that of unrelated people (Turnbaugh et al. 2009; Yatsunenکو et al. 2012). However, Rothschild et al. reported that environmental factors like diet, lifestyle, and drug interactions have a greater impact on our microbiome composition than host genetics, which only have a minor effect (Rothschild et al. 2018). The composition of our gut microbiota and our quality of life may both be significantly impacted by our living environment (Mueller et al. 2006).

Dietary habits, physical activity and the gut microbiota

The diet is one of the primary determinants of the composition, diversity, and function of the gut microbiota community, as shown by the most recent scientific research (Cotillard et al. 2013; Gibson et al. 2004; Sonnenburg and Bäckhed 2016; Zmora et al. 2018). Thus, lifelong dietary practices may contribute to inter-individual heterogeneity in the relative number of gut microbes and enterotype distribution (Cordain et al. 2005; Wu et al. 2011). A study that compared the fecal microbiota of Western European and African children from a community in Burkina Faso 10 years ago amply illustrated

the impact of intergenerational dietary practices on gut microbiota composition (De Filippo et al. 2010). The study's findings suggest that nutrition, more so than other significant factors like ethnicity, health, cleanliness, location, and climate, has a significant impact on how gut microbiota develops. Our gut microbiota's diversity and function have been significantly altered as a result of significant changes in diet and living conditions, particularly those brought about by industrial developments (such as processed foods, antibiotics, and clean environments), with significant implications for current outbreaks (Cordain et al. 2005; Sonnenburg and Sonnenburg, 2019; Sonnenburg and Sonnenburg, 2019). In addition to gastrointestinal issues, a number of other conditions may make it more difficult for older persons to meet their ideal nutritional needs (Nagpal et al. 2018; Saffrey 2014). For instance, a diminished desire and capacity to eat solid foods is one way that poor dental health might adversely influence nutritional status (Razak et al. 2014). For decades, regular physical activity and exercise have been linked to improved health and quality of life (Penedo and Dahn 2005). Additionally, it was shown that exercise promotes the generation of SCFA, improves intestinal mucosal immunity, and modifies the Firmicutes/Bacteroidetes ratio in the gut microbiota (Clarke et al. 2014a, b; Mach and Fuster-Botella 2017; Mailing et al. 2019; Monda et al. 2017). There is little information on the possible effects of exercise on gut microbiota in elderly individuals; however, several instances have recently been reported (Taniguchi et al. 2018; Zhu et al. 2020).

Concomitant disease and medication

Chronic sickness and disability are often more common as people age (Vos et al. 2017). Multiple drugs are frequently needed to treat various disorders, and long-term usage of these medications is frequently linked to an increased risk of adverse health effects (Maher et al. 2014). The interaction of various medications with the microbiota in the gut impacts both the therapeutic effect of the treatment as well as the composition and metabolic operation of the microbial ecology. Numerous prescription medications have been proven to be metabolized in part by our gut flora, which might help to explain some of the interindividual variation in reactions (efficacy and safety) (Zimmermann et al. 2019).

Medication exposure causing dysbiosis (antibiotics and proton pump inhibitors)

Antibiotics

In both medical settings and agriculture (Chang et al. 2015), the widespread (and usually excessive) use of broad-spectrum antibiotics raises two fundamental problems (Organization 2018). In contrast to rural, more

traditional cultures (Martínez et al. 2015; O’Keefe et al. 2015; Pasolli et al. 2019), it has led to the emergence of antibiotic (Davies and Davies 2010; Laxminarayan et al. 2013) resistance and a decrease in the variety of microbial species in our “industrial” microbiome (Blaser and Falkow 2009; Sonnenburg and Sonnenburg, 2019). Colonization resistance is one characteristic of a healthy microbiota (Nagpal et al. 2018; Sullivan et al. 2001), which protects against opportunistic strains and infections, and a microbiota that has been impacted by antibiotics, which may have fewer numbers and species, which can favor the establishment of opportunistic species like *Enterococcus faecalis* (Bartosch et al. 2004) and even increase the risk of *C. difficile* (Kwok et al. 2012). SCFA synthesis is also reduced by antibiotic treatment (Woodmansey et al. 2004), which are vital biological regulators of immunological responses and modulators of inflammation in older adults, and are produced as key metabolites during bacterial fermentation (Chambers et al. 2018; Ríos-Covián et al. 2016; Sanna et al. 2019).

Proton-pump inhibitors

Peptic ulcers and gastroesophageal reflux disease are two gastrointestinal conditions frequently treated with proton pump inhibitors (Olbe et al. 2003). Because they are considered low-risk, they are among the most often used drugs. Yet, new research has connected this to an increased risk of intestinal infections, notably *C. difficile* (Kwok et al. 2012; McDonald et al. 2015). Proton pump inhibitor usage over an extended period of time has been linked in more extensive studies to changes in the gut flora (Imhann et al. 2016; Jackson et al. 2016).

Chronic constipation, laxatives and dysbiosis

Chronic constipation is a common gastrointestinal illness that affects both the general population and the elderly in particular, with prevalence rates of around 20% in people over the age of 65 and 30% in persons over the age of 84 (women are more likely to experience chronic constipation than males) (Gallegos-Orozco et al. 2012). Laxatives are frequently used to relieve constipation symptoms (Ford and Suares 2011). However, certain laxatives can affect the gut flora long after being used for a short period of time (Tropini et al. 2018). A Dutch cohort study examining how various medications affected the composition and metabolic activity of the gut microbiota found that laxatives had one of the strongest connections with the microbiome (Vich Vila et al. 2020).

Obesity and dysbiosis

Even among older age groups, obesity and the issues it brings about are on the rise (Han et al. 2011; Mathus-Vliegen et al. 2012). Obesity alters the metabolism and

activities of the gut microbiome, as well as the relative abundance of the two major bacterial phyla, Bacteroidetes and Firmicutes, at the phylum level. It also reduces bacterial diversity and gene expression. The transplantation of microbiota in mice may also pass these features on (Ridaura et al. 2013; Turnbaugh et al. 2009). Alterations in the gut microbiota can therefore result in an increase in gut permeability and have an impact on insulin sensitivity, inflammation, and metabolic endotoxemia (Cani et al. 2007; Cani et al. 2009). Additionally, diabetes, cardiovascular disease, and several malignancies are significantly influenced by this low-grade inflammation (Cani and Jordan 2018).

Role and association between aging and physiological

Environmental elements, including diet, illness, and stress, combine with cellular, organ, and integrated system aging processes to create a complex interplay that determines how an organism ages. It’s never ideal to fully recover from insults that set off a pathological response. One of the true indicators of aging is the progressive variety in “physiology,” which includes the steady reduction of potential function (Young and Maguire 2019).

Age-related neurological loss, diminished neurotransmitter function, and reduced neurogenesis are the main causes of cognitive function decline. Delirium risk increases due to these alterations, which also cause slower mental processing and more perceptual impairment (Manor and Lipsitz 2013). Aging also throws off physiological rhythms, which include sleep cycles and the endocrine system. Deterioration of sensory organs, such as eyesight or hearing, can also lead to cognitive decline (Young and Maguire 2019).

There are lung structural changes that include reduced pulmonary rubber retreat, increased chest wall stiffness, and reduced respiratory muscle force generation capacity. These changes result in reduced mandatory critical capacity, forcible expiration volume in 1 second (FEV1) and critical capacity, and increased functional residual capacity (FRC). Changes in lung volume in the elderly are given in Fig. 1 (Young and Maguire 2019).

The aorta and carotid arteries are two examples of the major rubber arteries that constrict with age. The pre-decomposition and retreat of arterial waves are increased by a 50% rise in pulse wave velocity and a prolonged ejection, which also increases systolic and pulse pressure, cardiac effort, and oxygen demand (Mitchell 2008). Renal impairment and cerebrovascular events are caused by left ventricular hypertrophy, which is tissue damage resulting from increased pulse flow, particularly in high-flow organs. Furthermore, as people age, their b-adrenoceptor sensitivity declines, and their responsiveness to

B-agonists is diminished. This multifactorial decline in baroreflex includes diminished responsiveness of terminal organs, inadequate transmission of stretch signals, changed central neuronal processing, and altered autonomous baseline currents (Young and Maguire 2019).

After the age of 70–60, there is a rapid drop in physiological functional capacity (PFC) due to a decrease in maximal oxygen consumption (VO₂ max) and a decrease in the pace of training on the lactate threshold. Numerous physiological markers, including PFC, VO₂ max, aerobic capacity, vascular adaptability, and endothelium-dependent expansion, are all improved by regular aerobic exercise. Additionally, the oxyradical collecting capacity decreases the thickness of the intima-media wall, restores the endothelium (maintains the number of endothelial precursor cells), and boosts the fibrinolytic capacity (maintenance of endothelial tpa level) (Young and Maguire 2019).

Twenty percent less energy and physical activity are required to maintain the same level of basal metabolic rate. Other beneficial effects include lowering ATP-ASE NA activity, fat oxidation, gluconeogenesis, and altering the permeability of the mitochondrial membrane proton. Age-related anorexia is brought on by reduced ghrelin levels and increased cholecystokinin, which cause earlier satiety, quicker antral filling, and impaired taste and smell. Several anorexic cytokines, including ciliary nerve agent tnf-alpha, IL-1, IL-2, and IL-6, are implicated 20% less energy and physical activity are required to maintain the same level of basal metabolic rate. Other beneficial effects include lowering ATP-ASE NA activity, fat oxidation, gluconeogenesis, and altering the permeability of the mitochondrial membrane proton. Age-related anorexia is brought on by reduced ghrelin levels and increased cholecystokinin, which cause earlier satiety, quicker antral filling, and impaired taste and smell. Several anorexic cytokines, including ciliary nerve agent tnf-alpha, IL-1, IL-2, and IL-6, are implicated (Wilson and Morley 2003).

Role and association between aging and genetic

It may seem that aging and cancer are opposite processes: aging is marked by a loss of fitness, whereas cancer arises from an unnatural increase in cellular fitness. But perhaps there is a deeper connection between aging and cancer. It is generally accepted that the buildup of time-dependent cell damage is the primary cause of aging (Faggioli et al. 2012; Gems and Partridge 2013; Kirkwood 2005).

Both internal hazards, such as spontaneous hydrolytic processes, reactive oxygen species (ROS), mistakes in DNA replication, and external physical, chemical, and biological forces continuously threaten the integrity

and stability of DNA (Hoeijmakers 2009). The range of genetic lesions resulting from external or intrinsic insults is extensive and includes point mutations, transposons, chromosomal gain and loss, telomere shortening, and gene impairment due to virus or transposon mergers. In order to mitigate this damage, organisms have developed an intricate system of DNA repair mechanisms that, when combined, are capable of repairing the majority of nuclear DNA damage (Lord and Ashworth 2012). Moreover, direct DNA lesions in nuclear architectural deficiencies such as laminopathy might result in genomic instability and premature aging disorders (Worman 2012).

Older humans' and model creatures' cells accumulate somatic mutations (Moskalev et al. 2013). Aging is also linked to other types of DNA damage, including chromosomal aneuploids and variations in copy number (Faggioli et al. 2012; Forsberg et al. 2012). Pigmentosome subderma trichotidestrophy, cocaine syndrome, Werner syndrome, Bloom syndrome, Sekel syndrome, and other human progeroid syndromes are caused by a lack of DNA repair pathways, which also accelerates aging in animals (Gregg et al. 2012; Hoeijmakers 2009; Murga et al. 2009). Aging may also be influenced by aging-related mtDNA mutations and deletions (Park and Larsson 2011). The idea that mtDNA damage may be important for aging and age-related disorders was originally raised by the finding of multi-system human illnesses brought on by mtDNA mutations that partially phenocopy aging (Wallace 2005). Research on mice lacking the enzyme mitochondrial DNA polymerase provides more proof. The mtDNA mutation accumulation and random point deletions in these mutant mice cause them to age more quickly and live shorter lives (Kujoth et al. 2005; Trifunovic et al. 2004). Genome instability can also result from mtDNA abnormalities in the nuclear layer or genomic damage that affects the nucleus (Dechat et al. 2008). Nuclear laminate changes and the production of an abnormal prelamina isoform called progerin have also been identified during normal human aging (Ragnauth et al. 2010). In addition to these age-related changes in Type A laminas, Lamin B1 levels decrease during cellular aging, pointing to its application as a biomarker of this process (Freund et al. 2012; Shimi et al. 2011).

Role and association between aging and metabolic

Aging is a natural process associated with important metabolic changes in the body. At the cellular level, the function of the mitochondria responsible for generating energy in cells decreases. This means reducing cells' ability to produce energy and making more unstable use of metabolic fuels, such as glucose and fats. These mitochondrial changes may lead to a decrease in physical

strength and endurance in older people (López-Otín et al. 2013).

In addition, aging can have effects on internal balance and hormonal regulation of the body. In aging, the balance of hormones in the body may break down, which can lead to metabolic disorders such as diabetes and obesity. These hormonal changes may cause changes in body scale and fat distribution in the body (Kalyani and Egan 2013).

The inflammatory process also increases with aging. This means an increase in the level of inflammation in the body, which can lead to the destruction of tissues and disruption of the functioning of metabolic systems, including the immune system, cardiovascular system, and nervous system. Chronic inflammation over time can lead to damage and destruction of tissues, causing unwanted side effects (Franceschi et al. 2018).

Role and association between aging and immunological

Significant immune system alterations occur with aging. There are several aspects of aging that affect both the innate and adaptive immune systems. These include variations in the amount of dendritic and monocytic cells in the blood, a decrease in neutrophil phagocytic activity, restricted variation in B/T cell sets, T cell exhaustion or swelling, and the long-term production of inflammatory cytokines, or inflammation. Immunizations against infectious illnesses are less effective in older adults because their immune systems are not able to mount a strong enough resistance (Chan et al. 2019).

Figure 1 lists the cellular and molecular features of aging that have previously been reported, including immune system failure, sarcopenia, telomere erosion, epigenetic modifications, cellular aging, and mitochondrial dysfunction. Together with these features, chronic inflammation is thought to be the primary cause of aging and age-related disorders (López-Otín et al. 2013).

There are notable alterations in the innate and adaptive immune systems associated with aging. Aging may cause both quantitative and qualitative changes in innate immunity, such as a reduction in the quantity of circulating monocytic and dendritic cells (dcs), a downturn in the phagocytic activity of migrating macrophages or neutrophils, and an interference with the capacity of dcs to deliver AG. Because of the thymic complexity of maturity and the buildup of old, worn-out T cells that are either sleepy or functionally inefficient, aging can cause a reduction in the TCR complex in T cells. Age-related immune system disruption can result from a number of factors, such as persistent viral infection and the production of damage-associated molecular patterns (DAMPs)

(Gibson et al. 2016; Goronzy and Weyand 2013; Goronzy et al. 2001).

Multiple viruses cause persistent infections as host immune system escape mechanisms evolve. Certain viruses can be triggered to produce debilitating symptoms due to a lack of appropriate immunity, as well as delays at low viral replication levels. Elderly people who have infections, particularly respiratory tract infections, may experience consequences that increase their risk of illness and fatality (Chan et al. 2019).

Interventions to modulate gut microbiota in the elderly

Because dysbiosis, or an imbalance in the gut microbiota, has been linked to numerous health problems in humans (from metabolic to neurological disorders) (Cryan and Dinan 2012; Round and Mazmanian 2009; Sarkar et al. 2020; Zmora et al. 2019), Attempts to improve certain health outcomes by restoring a healthy microbiome have been the subject of extensive studies. Animal studies have been modified to include the human microbiome (Arrieta et al. 2016) to demonstrate causal relationships in people (Cryan and Dinan 2012; Round and Mazmanian 2009; Sarkar et al. 2020; Zmora et al. 2019).

Probiotics, prebiotics, and synbiotics

The bulk of health therapies over the past 20 years have included adding probiotics, substrates to encourage the growth of these beneficial bacteria (prebiotics), or a combination of both (synbiotics) to the human diet (Coman and Vodnar 2020).

Prebiotics

Three non-digestible oligosaccharides are effective in this field for prebiotic interventions, which are defined as “a selectively fermented substance that enables specific changes, both in composition and/or activity, in the gastrointestinal microflora that confer benefits on the health and well-being of the host” (Gibson et al. 2004). These are xylo-oligosaccharides (XOS) (Chung et al. 2007), galacto-oligosaccharides (GOS) (Vulevic et al. 2015), and fructo-oligosaccharides (FOS) (Scheid et al. 2014). According to Vazquez et al. (2000), xylose subunits, which make up XOS, have great prebiotic potential and crucial food-related uses (Vazquez et al. 2000). According to studies, GOS are significant prebiotic components of functional foods and are made up of β -linked galactose subunits (Sangwan et al. 2011; Torres et al. 2010). Due to their prebiotic properties, FOS, which are made up of linear chains of fructose connected by (2-1) connections, are frequently utilized in food (Sabater-Molina et al. 2009; Sangeetha et al. 2005). The quantity of fecal bifidobacteria is dramatically increased by XOS use. According to

Pokusaeva et al. bifidobacteria can identify different oligos and saccharides in the human gut (Pokusaeva et al. 2011) and have a positive impact on health (O’Callaghan and Van Sinderen 2016). During the course of the trial, no negative impacts on blood counts, nutritional intake, or gastrointestinal (GI) health were seen (Chung et al. 2007). The ingestion of GOS has a bifidogenic impact, which may also be detected immunologically by an increase in IL-10 production and a notable rise in NK cell activity (lymphocytes with the main role against viral infections and some malignancies) (Shaw et al. 2010). In contrast to a placebo (maltodextrin), the intervention of FOS supplementation on blood pharmaceuticals (glucose and lipids) and intestinal transit was shown to minimize the effect of medicines on serum glucose, but no effect of FOS on serum lipids or intestinal transmission was detected. Nothing unfavorable happened, such as gas or discomfort in the abdomen (Scheid et al. 2014).

Probiotics

Live bacteria that provide health advantages when taken in appropriate concentrations are known as probiotics (Hill et al. 2014). Probiotics have been demonstrated to be helpful in the treatment and management of gastrointestinal disorders and immunological responses to respiratory viruses generally in adult populations by longitudinal meta-analyses of RCTs (Ritchie and Romanuk 2012). Diet and lifestyle, age, comorbidities, exposure to biotic risks, and the make-up and function of the basal microbiota are examples of host variables that may affect the effectiveness of an intervention (Suez et al. 2020).

Probiotics aid the intestines by strengthening the immune system and balancing out inflammation brought

on by an invading foreign body (Ashaolu 2020). Along with dendritic and epithelial cells, they also cooperate with monocytes and lymphocytes, which are crucial for both innate and adaptive immunity. Probiotics can enhance mucosal immune responses by decreasing the expression of pro-inflammatory cytokines like TNF and IFN-γ, thereby inducing anti-inflammatory cytokines like IL-10 and TGF-β (Corr et al. 2007; Di Giacinto et al. 2005). Furthermore, certain probiotic microbes employ cellular surface features, including fimbrias and capsules, as mechanical stimulation for immune-boosting processes (Sanders et al. 2019).

Cloning resistance is a notion that most likely results from the coordinated action of several immune-boosting processes brought forth by probiotics. This phenomenon is defined as the intestinal intrinsic microbiota occupying host tissue with the aim of eliminating potentially harmful pathogens (Chiu et al. 2017).

The production of antimicrobial compounds is one of the efficacious processes via which probiotics benefit the host by strengthening human immunity and protecting against gastrointestinal infections. Competitive eradication for food sources and binding sites enhanced immune system regulation, and gut barrier are some of the mechanisms through which probiotics exert their beneficial effects (Wan et al. 2019). Probiotics generate a variety of compounds, including bacteriocins, hydrogen peroxide, and organic acids, as a result of their antimicrobial activity (Fig. 5).

These compounds have the ability to kill both gram-positive and gram-negative bacteria. Bacteriocins are produced by many *Lactobacillus* strains. The mechanism of action involves blocking the creation of cell walls or




Fig. 5 The immunomodulatory effects of probiotics: enhancing immunity and protecting against inflammation and infections

creating pores, which kills the target pathogenic cells. Additionally, the release of antimicrobial compounds, such as acetic and lactic acids, acidifies the environment to prevent the growth of pathogens like Salmonella. This acidification inhibits nutrient transport, leading to bactericidal consequences (De Keersmaecker et al. 2006; Russell and Diez-Gonzalez 1997). Furthermore, microcin is secreted by probiotic bacteria and works by binding to iron-siderophore receptors to either enter the cell or cause the production of hazardous compounds once inside. These mechanisms result in the suppression of intracellular enzymes, including RNA polymerase, DNA gyrase, and ATP synthase, as well as their activities, such as mRNA translation, ultimately leading to the death of pathogenic cells. The competitive elimination process involves binding locations and nutritional rivalry between pathogenic and probiotic organisms. Probiotics can halt the development of pathogens by employing surface protein structures like mucins or using antimicrobial secretions like organic acids to create an inhospitable environment for infections. Certain research indicates that the expression of tight junction signaling-related genes increases when probiotics are consumed, thereby maintaining the integrity of the intestinal barrier intact (Wan et al. 2019).

Probiotics like *Lactobacillus acidophilus* (LAB) and *Bifidobacteria* can boost the expression of polymeric immunoglobulin receptors (pIgR), which may help prevent invasion of the mucous barrier. It is important to note that LAB can influence intestinal dendritic cells and epithelial cells (Kikuchi et al. 2014; Sakai et al. 2014). Certain components of LAB have the ability to trigger dendritic cell production of TGF- β or IL-6 via TLR2 (47). Moreover, lactic acid bacteria use polysaccharides to promote NK activity, which in turn boosts host defense by stimulating the synthesis of IL-12 (Hachimura et al. 2018).

Synbiotics

Synbiotics: Using probiotics and prebiotics together is another option for managing the microbiota (Caso et al. 2013). Probiotics, or live microbial additions, can be used in combination with certain prebiotic substrates (such as lactitol and *Lactobacillus* organisms or fructooligosaccharide and bifidobacterial strains) to promote development. Due to the compound's easily accessible specialized substrate for fermentation and the advantages that a live prebiotic bacterium provides for the host, it can increase the probiotic organism's chances of survival (Palmer and Jensen 2022).

In the realm of vaccination, it has been extensively studied how geriatric immune system function is affected. It revealed an increase in monocyte and

granulocyte phagocytic activity (the main mechanism in clearing pathogens). Consuming synbiotics also led to changes in the microbiota's composition (a rise in Bifidobacteria, Firmicutes, and Actinobacteria vs a decline in Proteobacteria), as well as an increase in butyrate synthesis (Maneerat et al. 2013). Finally, the use of synbiotics demonstrated a considerable reduction in various cardiovascular risk variables and indications of insulin resistance (Cicero et al. 2021; Costabile et al. 2017).

Fecal microbiota transplantation

For patients who have experienced several recurrences of *C. difficile* infection and have not responded to proper antibiotic treatment, current clinical recommendations from the United States advise FMT (L. C. McDonald et al. 2018). This advice is supported by multiple RCTs that show fecal microbiota transplantation (FMT) to be a successful alternative treatment for *C. difficile* infection (Cammarota et al. 2015; Kelly et al. 2016; Lee et al. 2016; Van Nood et al. 2013; Youngster et al. 2014). Elderly persons are disproportionately impacted by *C. difficile* infection, according to research (Keller and Surawicz 2014; Smits et al. 2016). This is mostly due to worries about safety, greater exposure in hospital settings, and regular use of antibiotics and proton pump inhibitors (Loo et al. 2011).

Conclusion

Along with its role in metabolism and immune system control, the gut's microbial diversity declines as we become older. This presents a window of opportunity for opportunistic microorganisms to enter and inflame the gut, resulting in a range of illnesses from low-grade chronic sickness to hospitalizations and even death. There has been a lot of study on the gut microbiota, but it has not yet been possible to pinpoint the best method for treating or preventing dysbiosis in the elderly. Over the course of a person's life, diet may influence the gut microbiota, and older persons may benefit the most from this. It is almost likely that using broad-spectrum antibiotics harms the gut flora. The diversity of the gut microbiota can be restored, and probiotic supplementation has a strong potential to do both.

Informed consent

Not applicable.

Authors' contributions

FS, MK: design of study. FS, MV, BP, HOA, ST, AH, AHA: acquisition of data. FS, MV, BP, HOA, AA, QAQ: evaluation of data, preparation of the manuscript. MK, BP, HOA: assessment of data. All authors read and approved the final manuscript.

Funding

This paper was not funded.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Received: 28 September 2023 Accepted: 11 December 2023

Published online: 03 January 2024

References

- Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Ribeiro-Dias F (2008) Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. *J Clin Invest* 118(1):205–216
- Al Nabhani Z, Dulauroy S, Marques R, Cousu C, Al Bounny S, Déjardin F, Eberl G (2019) A weaning reaction to microbiota is required for resistance to immunopathologies in the adult. *Immunity* 50(5):1276–1288. E1275
- Alarcón RC, Rojo IC (2020). Microbiota intestinal y envejecimiento. *Geroinfo* 15(1)
- Amorim NM, Kee A, Coster AC, Lucas C, Bould S, Daniel S, Meikle PJ (2020) Irradiation impairs mitochondrial function and skeletal muscle oxidative capacity: significance for metabolic complications in cancer survivors. *Metabolism* 103:154025
- Arbolea S, Sánchez B, Solís G, Fernández N, Suárez M, Hernández-Barranco AM, Ventura M (2016) Impact of prematurity and perinatal antibiotics on the developing intestinal microbiota: a functional inference study. *Int J Mol Sci* 17(5):649
- Arrieta M-C, Walter J, Finlay BB (2016) Human microbiota-associated mice: a model with challenges. *Cell Host Microbe* 19(5):575–578
- Ashaolu TJ (2020) Immune boosting functional foods and their mechanisms: a critical evaluation of probiotics and prebiotics. *Biomed Pharmacother* 130:110625
- Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, Tanoue T (2017) Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. *Science* 358(6361):359–365
- Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Gordon JI (2004) The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci* 101(44):15718–15723
- Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Monteith P (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. *PLoS One* 8(4):e60042
- Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Gillevet PM (2012) Linkage of gut microbiome with cognition in hepatic encephalopathy. *Am J Physiol-Gastrointest Liver Physiol* 302(1):G168–G175
- Bartosch S, Fite A, Macfarlane GT, McMurdo ME (2004) Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. *Appl Environ Microbiol* 70(6):3575–3581
- Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. *Cell* 157(1):121–141
- Benítez-Páez A, Olivares M, Szajewska H, Pieścik-Lech M, Polanco I, Castillejo G, Koletzko S (2020) Breast-milk microbiota linked to celiac disease development in children: a pilot study from the PreventCD cohort. *Front Microbiol* 11:1335
- Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S, Monti D (2016) Gut microbiota and extreme longevity. *Curr Biol* 26(11):1480–1485
- Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Franceschi C (2010) Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 5(5):e10667
- Blachier F, Mariotti F, Huneau J-F, Tomé D (2007) Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences. *Amino Acids* 33:547–562
- Blaser MJ, Falkow S (2009) What are the consequences of the disappearing human microbiota? *Nat Rev Microbiol* 7(12):887–894
- Bradley CP, Teng F, Felix KM, Sano T, Naskar D, Block KE, Wu H-JJ (2017) Segmented filamentous bacteria provoke lung autoimmunity by inducing gut-lung axis Th17 cells expressing dual TCRs. *Cell Host Microbe* 22(5):697–704. e694
- Brand EC, Klaassen MA, Gacesa R, Vila AV, Ghosh H, De Zoete MR, van de Meeberg PC (2021) Healthy cotwins share gut microbiome signatures with their inflammatory bowel disease twins and unrelated patients. *Gastroenterology* 160(6):1970–1985
- Britton GJ, Contijoch EJ, Spindler MP, Aggarwala V, Dogan B, Bongers G, Gevers D (2020) Defined microbiota transplant restores Th17/RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. *Proc Natl Acad Sci* 117(35):21536–21545
- Bron PA, Grangette C, Mercenier A, De Vos WM, Kleerebezem M (2004) Identification of *Lactobacillus plantarum* genes that are induced in the gastrointestinal tract of mice. *J Bacteriol* 186(17):5721–5729
- Brook I (1996) *Veillonella* infections in children. *J Clin Microbiol* 34(5):1283–1285
- Cammarota G, Masucci L, Ianiro G, Bibbo S, D'Ino G, Costamagna G, Gasbarrini A (2015) Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Alimentary Pharmacol Ther* 41(9):835–843
- Canfora EE, van der Beek CM, Hermes GD, Goossens GH, Jocken JW, Holst JJ, Zoetendal EG (2017) Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. *Gastroenterology* 153(1):87–97. e83
- Canfi PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Chabo C (2007) Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 56(7):1761–1772
- Canfi PD, Jordan BF (2018) Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. *Nat Rev Gastroenterol Hepatol* 15(11):671–682
- Canfi PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Lambert DM (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut* 58(8):1091–1103
- Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Mowry EM (2015) Gut microbiota in multiple sclerosis: possible influence of immunomodulators. *J Investig Med* 63(5):729–734
- Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Fierer N (2011) Moving pictures of the human microbiome. *Genome Biol* 12(5):1–8
- Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, Ropelle ER, Camara NO (2011) Gut microbiota is a key modulator of insulin resistance in TLR2 knockout mice. *PLoS Biol* 9(12):e1001212
- Caso G, McNurlan MA, Mileva I, Zemlyak A, Mynarcik DC, Gelato MC (2013) Peripheral fat loss and decline in adipogenesis in older humans. *Metabolism* 62(3):337–340
- Chambers ES, Preston T, Frost G, Morrison DJ (2018) Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. *Curr Nutr Rep* 7:198–206
- Chan CX, Yang YO, Cheng GHM, Gera SK, Mohammad A. b. Z, Oh SJ, Shin OS (2019) Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity. *Immune Network* 11(4):e37
- Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage WP (2015) Antibiotics in agriculture and the risk to human health: how worried should we be? *Evol Appl* 8(3):240–247
- Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Chen X (2016) Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci Rep* 6(1):1–10

- Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Taneja V (2016) An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med* 8(1):1–14
- Chiu L, Bazin T, Truchetet M-E, Schaevebeke T, Delhaes L, Pradeu T (2017) Protective microbiota: from localized to long-reaching co-immunity. *Front Immunol* 8:1678
- Chung Y-C, Hsu C-K, Ko C-Y, Chan Y-C (2007) Dietary intake of xylooligosaccharides improves the intestinal microbiota, fecal moisture, and pH value in the elderly. *Nutr Res* 27(12):756–761
- Cicero AF, Fogacci F, Bove M, Giovannini M, Borghi C (2021) Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. *Eur J Nutr* 60:655–663
- Claesson MJ, Jeffery IB, Conde S, Power SE, O'connor EM, Cusack S, O'sullivan O (2012) Gut microbiota composition correlates with diet and health in the elderly. *Nature* 488(7410):178–184
- Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG (2014) Minireview: gut microbiota: the neglected endocrine organ. *Mol Endocrinol* 28(8):1221–1238
- Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Wood-Martin R (2014) Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* 63(12):1913–1920
- Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. *Lancet* 381(9868):752–762
- Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on human health: an integrative view. *Cell* 148(6):1258–1270
- Coman V, Vodnar DC (2020) Gut microbiota and old age: Modulating factors and interventions for healthy longevity. *Exp Gerontol* 141:111095
- Cong X, Xu W, Janton S, Henderson WA, Matson A, McGrath JM, Graf J (2016) Gut microbiome developmental patterns in early life of preterm infants: impacts of feeding and gender. *PLoS One* 11(4):e0152751
- Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, Brand-Miller J (2005) Origins and evolution of the Western diet: health implications for the 21st century. *Am J Clin Nutr* 81(2):341–354
- Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG (2007) Bacteriocin production as a mechanism for the anti-infective activity of *Lactobacillus salivarius* UCC118. *Proc Natl Acad Sci* 104(18):7617–7621
- Costabile A, Bergillos-Meca T, Rasinkangas P, Korpela K, De Vos WM, Gibson GR (2017) Effects of soluble corn fiber alone or in synbiotic combination with *Lactobacillus rhamnosus* GG and the pilus-deficient derivative GG-PB12 on fecal microbiota, metabolism, and markers of immune function: a randomized, double-blind, placebo-controlled, crossover study in healthy elderly (Saimes study). *Front Immunol* 8:1443
- Costea PI, Hildebrand F, Arumugam M, Bäckhed F, Blaser MJ, Bushman FD, Hattori M (2018) Enterotypes in the landscape of gut microbial community composition. *Nat Microbiol* 3(1):8–16
- Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Galleron N (2013) Dietary intervention impact on gut microbial gene richness. *Nature* 500(7464):585–588
- Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nat Rev Neurosci* 13(10):701–712
- Cusick MF, Libbey JE, Fujinami RS (2012) Molecular mimicry as a mechanism of autoimmune disease. *Clin Rev Allergy Immunol* 42:102–111
- Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A-L, Barnich N, Colombel J-F (2004) High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. *Gastroenterology* 127(2):412–421
- Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 74(3):417–433
- Davila A-M, Blachier F, Gotteland M, Andriamihaja M, Benetti P-H, Sanz Y, Tomé D (2013) Re-print of "Intestinal luminal nitrogen metabolism: Role of the gut microbiota and consequences for the host." *Pharmacol Res* 69(1):114–126
- De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poulet JB, Massart S, Lionetti P (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci* 107(33):14691–14696
- De Keersmaecker SC, Verhoeven TL, Desair J, Marchal K, Vanderleyden J, Nagy I (2006) Strong antimicrobial activity of *Lactobacillus rhamnosus* GG against *Salmonella typhimurium* is due to accumulation of lactic acid. *FEMS Microbiol Lett* 259(1):89–96
- de Punder K, Pruimboom L (2015) Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. *Front Immunol* 6:223
- Dechat T, Pfliegerhaer K, Sengupta K, Shimi T, Shumaker DK, Solimando L, Goldman RD (2008) Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. *Genes Dev* 22(7):832–853
- DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E (2016) Current understanding of dysbiosis in disease in human and animal models. *Inflamm Bowel Dis* 22(5):1137–1150
- Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF- β -bearing regulatory cells. *J Immunol* 174(6):3237–3246
- Differding MK, Benjamin-Neelon SE, Hoyo C, Østbye T, Mueller NT (2020) Timing of complementary feeding is associated with gut microbiota diversity and composition and short chain fatty acid concentrations over the first year of life. *BMC Microbiol* 20(1):1–13
- Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci* 107(26):11971–11975
- Duszka K, Gregor A, Guillou H, König J, Wahli W (2020) Peroxisome proliferator-activated receptors and caloric restriction—common pathways affecting metabolism, health, and longevity. *Cells* 9(7):1708
- English J, Connolly L, Stewart LD (2023) Increased Intestinal Permeability: An Avenue for the Development of Autoimmune Disease? *Exposure Health* 19:1–31
- Escobar MF, Hincapie MA, Barona JS (2020) Immunological role of the maternal uterine microbiota in postpartum hemorrhage. *Front Immunol* 11:504
- Faggioli F, Wang T, Vijg J, Montagna C (2012) Chromosome-specific accumulation of aneuploidy in the aging mouse brain. *Human Mol Genet* 21(24):5246–5253
- Fallani M, Amarrì S, Uusijärvi A, Adam R, Khanna S, Aguilera M, Young D (2011) Determinants of the human infant intestinal microbiota after the introduction of first complementary foods in infant samples from five European centres. *Microbiology* 157(5):1385–1392
- Favier M-L, Moundras C, Demigné C, Rémésy C (1995) Fermentable carbohydrates exert a more potent cholesterol-lowering effect than cholestyramine. *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism* 1258(2):115–121
- Fluitman KS, De Clercq NC, Keijsers BJ, Visser M, Nieuwdorp M, IJzerman R G. (2017) The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids. *Exp Rev Endocrinol Metab* 12(3):215–226
- Ford AC, Suarez NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. *Gut* 60(2):209–218
- Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Boomsma D (2012) Age-related somatic structural changes in the nuclear genome of human blood cells. *Am J Human Genet* 90(2):217–228
- Franceschi C (2007) Inflammaging as a major characteristic of old people: can it be prevented or cured? *Nutr Rev* 65(suppl_3):S173–S176
- Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) Inflammaging: a new immune–metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* 14(10):576–590
- Freund A, Laberge R-M, Demaria M, Campisi J (2012) Lamin B1 loss is a senescence-associated biomarker. *Mol Biol Cell* 23(11):2066–2075
- Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM (2012) Chronic constipation in the elderly. *Am Coll Gastroenterol* 107(1):18–25
- Ganal-Vonarburg SC, Hornef MW, Macpherson AJ (2020) Microbial–host molecular exchange and its functional consequences in early mammalian life. *Science* 368(6491):604–607
- Gems D, Partridge L (2013) Genetics of longevity in model organisms: debates and paradigm shifts. *Ann Rev Physiol* 75:621–644
- Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Yassour M (2014) The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe* 15(3):382–392

- Gibson GR, Probert HM, Van Loo J, Rastall RA, Roberfroid MB (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev* 17(2):259–275
- Gibson M, Wang B, Ahmadi S, Burnham C, Tarr P, Warner B, Dantas G (2016) Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome. *Nat Microbiol*. 1:16024
- Godefroy E, Alameddine J, Montassier E, Mathé J, Desfrancois-Noël J, Marec N, Le Roy A (2018) Expression of CCR6 and CXCR6 by gut-derived CD4+/CD8α+ T-regulatory cells, which are decreased in blood samples from patients with inflammatory bowel diseases. *Gastroenterology* 155(4):1205–1217
- Gomes AC, Hoffmann C, Mota JF (2018) The human gut microbiota: Metabolism and perspective in obesity. *Gut Microbes* 9(4):308–325
- Goronzy JJ, Weyand CM (2013) Understanding immunosenescence to improve responses to vaccines. *Nat Immunol* 14(5):428–436
- Goronzy J, r. J., Fulbright, J. W., Crowson, C. S., Poland, G. A., O'Fallon, W. M., & Weyand, C. M. (2001) Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. *J Virol* 75(24):12182–12187
- Goyal A, Dubinkina V, Maslov S (2018) Multiple stable states in microbial communities explained by the stable marriage problem. *ISME J* 12(12):2823–2834
- Gregg SQ, Gutiérrez V, Robinson AR, Woodell T, Nakao A, Ross MA, Kamileri I (2012) A mouse model of accelerated liver aging caused by a defect in DNA repair. *Hepatology* 55(2):609–621
- Hachimura S, Totsuka M, Hosono A (2018) Immunomodulation by food: impact on gut immunity and immune cell function. *Biosci Biotechnol Biochem* 82(4):584–599
- Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R (2008) Error-correcting bar-coded primers for pyrosequencing hundreds of samples in multiplex. *Nat Methods* 5(3):235–237
- Han T, Tajar A, Lean M (2011) Obesity and weight management in the elderly. *Br Med Bull* 97(1):169–196
- Harmsen, H. J., & de Goffau, M. C. (2016). The human gut microbiota. *Microbiota Hum Body*. 95–108
- Hesla HM, Stenius F, Jäderlund L, Nelson R, Engstrand L, Alm J, Dicksved J (2014) Impact of lifestyle on the gut microbiota of healthy infants and their mothers—the ALADDIN birth cohort. *FEMS Microbiol Ecol* 90(3):791–801
- Hildebrand F, Gossmann TI, Frioux C, Özkurt E, Myers PN, Ferretti P, Bork P (2021) Dispersal strategies shape persistence and evolution of human gut bacteria. *Cell Host Microbe* 29(7):1167–1176. e1169
- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Salminen S (2014) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*
- Hill CJ, Lynch DB, Murphy K, Ulaszewska M, Jeffery IB, O'Shea CA, Tuohy K (2017) Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. *Microbiome* 5:1–18
- Ho NT, Li F, Lee-Sarwar KA, Tun HM, Brown BP, Pannaraj PS, Weiss ST (2018) Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations. *Nat Commun* 9(1):4169
- Hoeijmakers JH (2009) DNA damage, aging, and cancer. *N Engl J Med* 361(15):1475–1485
- Hoffmann TW, Pham H-P, Bridonneau C, Aubry C, Lamas B, Martin-Gallausiaux C, Six A (2016) Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. *ISME J* 10(2):460–477
- Ilhan N (2018) Gut microbiota and metabolism. *Int J Med Biochem* 1(3):115–128
- Imhann F, Bonder MJ, Vila AV, Fu J, Mujagic Z, Vork L, Harmsen HJ (2016) Proton pump inhibitors affect the gut microbiome. *Gut* 65(5):740–748
- Ivanov II, de Llanos Frutos R, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Littman DR (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe* 4(4):337–349
- Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, Bell JT (2016) Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 65(5):749–756
- Jeffery IB, Lynch DB, O'toole P. W (2016) Composition and temporal stability of the gut microbiota in older persons. *The ISME journal* 10(1):170–182
- Jhingi S, Gandhi R, Glanz B, Cook S, Nejad P, Ward D, Weiner H (2014) Increased Archaea species and changes with therapy in gut microbiome of multiple sclerosis subjects (S24. 001). *AAN Enterprises*
- Jia W, Whitehead RN, Griffiths L, Dawson C, Bai H, Waring RH, Bessant C (2012) Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. *FEMS ImmunolMed Microbiol* 65(1):55–68
- Jiao Y, Wu L, Huntington ND, Zhang X (2020) Crosstalk between gut microbiota and innate immunity and its implication in autoimmune diseases. *Front Immunol* 11:282
- Kalyani RR, Egan JM (2013) Diabetes and altered glucose metabolism with aging. *Endocrinol Metab Clin* 42(2):333–347
- Keller JM, Surawicz CM (2014) Clostridium difficile infection in the elderly. *Clin Geriatr Med* 30(1):79–93
- Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Tisch A (2016) Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. *Ann Int Med* 165(9):609–616
- Kikuchi Y, Kunitoh-Asari A, Hayakawa K, Imai S, Kasuya K, Abe K, Hachimura S (2014) Oral administration of Lactobacillus plantarum strain AYA enhances IgA secretion and provides survival protection against influenza virus infection in mice. *PLoS One* 9(1):e86416
- Kim HB, Borewicz K, White BA, Singer RS, Sreevatsan S, Tu ZJ, Isaacson RE (2011) Longitudinal investigation of the age-related bacterial diversity in the feces of commercial pigs. *Vet Microbiol* 153(1–2):124–133
- Kirkwood TB (2005) Understanding the odd science of aging. *Cell* 120(4):437–447
- Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Ley RE (2011) Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci* 108(1):4578–4585
- Kohl HW, Craig CL, Lambert EV, Inoue S, Alkandari JR, Leetongin G, Kahlmeier S (2012) The pandemic of physical inactivity: global action for public health. *Lancet* 380(9838):294–305
- Korpela K, Blakstad EW, Moltu SJ, Strømmen K, Nakstad B, Rønnestad AE, Brække K, Iversen PO, Drevon CA, de Vos W (2018) Intestinal microbiota development and gestational age in preterm neonates. *Sci Rep* 8(1):2453
- Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Bäckhed F (2015) Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. *Cell Metab* 22(6):971–982
- Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Jobling W (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science* 309(5733):481–484
- Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and anti-biotics: Meta-analysis. *Am Coll Gastroenterol* 107(7):1011–1019
- Lagier J-C, Million M, Hugon P, Armougom F, Raoult D (2012) Human gut microbiota: repertoire and variations. *Front Cell Infect Microbiol* 2:136
- Lahtinen SJ, Tammela L, Korpela J, Parhiala R, Ahokoski H, Mykkänen H, Salminen SJ (2009) Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents. *Age* 31:59–66
- Lallès J-P, Bosi P, Smidt H, Stokes CR (2007) Weaning—A challenge to gut physiologists. *Livestock Sci* 108(1–3):82–93
- Lamas B, Richard ML, Leducq V, Pham H-P, Michel M-L, Da Costa G, Natividad JM (2016) CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nat Med* 22(6):598–605
- Laursen MF, Andersen LB, Michaelsen KF, Mølgaard C, Trolle E, Bahl MI, Licht TR (2016) Infant gut microbiota development is driven by transition to family foods independent of maternal obesity. *MSphere* 1(1):e00069-00015
- Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Goossens H (2013) Antibiotic resistance—the need for global solutions. *Lancet Infect Dis* 13(12):1057–1098
- Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Crowther M (2016) Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. *JAMA* 315(2):142–149

- Lee YK, Mazmanian SK (2010) Has the microbiota played a critical role in the evolution of the adaptive immune system? *Science* 330(6012):1768–1773
- Lee YK, Menezes JS, Umesaki Y, Mazmanian SK (2011) Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci* 108(1):4615–4622
- Leschelle X, Robert V, Delpal S, Mouille B, Mayeur C, Martel P, Blachier F (2002) Isolation of pig colonic crypts for cytotoxic assay of luminal compounds: effects of hydrogen sulfide, ammonia, and deoxycholic acid. *Cell Biol Toxicol* 18:193–203
- Levrat M-A, Favier M-L, Moundras C, Rémésy C, Demigné C, Morand C (1994) Role of dietary propionic acid and bile acid excretion in the hypocholesterolemic effects of oligosaccharides in rats. *J Nutr* 124(4):531–538
- Levrat M-A, Rémésy C, Demigné C (1991) High propionic acid fermentations and mineral accumulation in the cecum of rats adapted to different levels of inulin. *J Nutr* 121(11):1730–1737
- Li X-X, Liao A-M, Dong Y-Q, Hou Y, Pan L, Li C, Huang J-H (2022) In vitro dynamic digestion and anti-fatigue effects of wheat embryo albumin. *Food Function* 13(5):2559–2569
- Lin L, Zhang J (2017) Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. *BMC Immunol* 18:1–25
- Lin Y, Vonk RJ, Slooff MJ, Kuipers F, Smit MJ (1995) Differences in propionate-induced inhibition of cholesterol and triacylglycerol synthesis between human and rat hepatocytes in primary culture. *Br J Nutr* 74(2):197–207
- Ling Z, Liu X, Cheng Y, Yan X, Wu S (2022) Gut microbiota and aging. *Crit Rev Food Sci Nutr* 62(13):3509–3534
- Liu X, Zou Q, Zeng B, Fang Y, Wei H (2013) Analysis of fecal *Lactobacillus* community structure in patients with early rheumatoid arthritis. *Curr Microbiol* 67:170–176
- Liu Y, Qin S, Song Y, Feng Y, Lv N, Xue Y, Ma J (2019) The perturbation of infant gut microbiota caused by cesarean delivery is partially restored by exclusive breastfeeding. *Front Microbiol* 10:598
- Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Gilca R (2011) Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med* 365(18):1693–1703
- Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A (2018) The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. *Exp Opin Investig Drugs* 27(6):543–551
- López-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. *Cell* 153(6):1194–1217
- Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. *Nature* 481(7381):287–294
- Loubinoux J, Bronowicki J-P, Pereira IA, Mougénel J-L, Le Faou AE (2002) Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiol Ecol* 40(2):107–112
- Luan Z, Sun G, Huang Y, Yang Y, Yang R, Li C, Jun C (2020) Metagenomics study reveals changes in gut microbiota in centenarians: a cohort study of hainan centenarians. *Front Microbiol* 11:1474
- Mach N, Fuster-Botella D (2017) Endurance exercise and gut microbiota: a review. *J Sport Health Sci* 6(2):179–197
- Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, Narazaki M (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. *Arthr Rheumatol* 68(11):2646–2661
- Maeda Y, Takeda K (2019) Host–microbiota interactions in rheumatoid arthritis. *Exp Mol Med* 51(12):1–6
- Magne F, Puchi Silva A, Carvajal B, Gotteland M (2017) The elevated rate of cesarean section and its contribution to non-communicable chronic diseases in Latin America: the growing involvement of the microbiota. *Front Pediatr* 5:192
- Magrone T, Jirillo E (2013) The interaction between gut microbiota and age-related changes in immune function and inflammation. *Immunity Ageing* 10:1–6
- Mahajan P, Kulkarni A, Bandre A, Subramanian S, Mahajan S (2021) Role of gut microbiota in autoimmune diseases: a review. *J Vacc Immunol* 6(163):1–14
- Maher RL, Hanlon J, Hajjar ER (2014) Clinical consequences of polypharmacy in elderly. *Exp Opin Drug Saf* 13(1):57–65
- Mailing LJ, Allen JM, Buford TW, Fields CJ, Woods JA (2019) Exercise and the gut microbiome: a review of the evidence, potential mechanisms, and implications for human health. *Exerc Sport Sci Rev* 47(2):75–85
- Maneerat S, Lehtinen MJ, Childs CE, Forssten SD, Alhoniemi E, Tiphaine M, Rastall RA (2013) Consumption of *Bifidobacterium lactis* Bi-07 by healthy elderly adults enhances phagocytic activity of monocytes and granulocytes. *J Nutr Sci* 2:e44
- Manimozhiyan A, Jeroen R, Eric P, Denis LP, Takuji Y, Daniel RM, Jean-Michel B (2011) Enterotypes of the human gut microbiome. *Nature* 473(7346):174–180
- Manor B, Lipsitz LA (2013) Physiologic complexity and aging: Implications for physical function and rehabilitation. *Prog Neuro-Psychopharmacol Biol Psychiatry* 45:287–293
- Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Doré J, Furet J (2009) The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol* 9(1):1–6
- Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Darfeuille-Michaud A (2009) Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIIEC) in Crohn's disease. *Inflamm Bowel Dis* 15(6):872–882
- Martínez I, Stegen JC, Maldonado-Gómez MX, Eren AM, Siba PM, Greenhill AR, Walter J (2015) The gut microbiota of rural papua new guineans: composition, diversity patterns, and ecological processes. *Cell Rep* 11(4):527–538
- Mateos I, Combes S, Pascal G, Cauquil L, Barilly C, Cossalter A-M, Oswald IP (2018) Fumonisin-exposure impairs age-related ecological succession of bacterial species in weaned pig gut microbiota. *Toxins* 10(6):230
- Mathus-Vliegen EM, Basdevant A, Finer N, Hainer V, Hauner H, Micic D, Tsigos C (2012) Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. *Obes Facts* 5(3):460–483
- McDonald EG, Milligan J, Frenette C, Lee TC (2015) Continuous proton pump inhibitor therapy and the associated risk of recurrent *Clostridium difficile* infection. *JAMA Intern Med* 175(5):784–791
- McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Kelly C (2018) Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 66(7):e1–e48
- Mitchell GF (2008) Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol* 105(5):1652–1660
- Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Reinisch W (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology* 149(1):102–109. e106
- Monda V, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, Monda M (2017) Exercise modifies the gut microbiota with positive health effects. *Oxid Med Cellular Longev* 2017
- Morrison KE, Jašarević E, Howard CD, Bale TL (2020) It's the fiber, not the fat: significant effects of dietary challenge on the gut microbiome. *Microbiome* 8:1–11
- Moskalev AA, Shaposhnikov MV, Plyusnina EN, Zhavoronkov A, Budovsky A, Yanai H, Fraifeld VE (2013) The role of DNA damage and repair in aging through the prism of Koch-like criteria. *Ageing Res Rev* 12(2):661–684
- Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, Verdenelli MC (2006) Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 72(2):1027–1033
- Mulder DJ, Noble AJ, Justinich CJ, Duffin JM (2014) A tale of two diseases: the history of inflammatory bowel disease. *J Crohn's Colit* 8(5):341–348
- Munukka E, Wiklund P, Pekkala S, Völggi E, Xu L, Cheng S, Vahtovuo J (2012) Women with and without metabolic disorder differ in their gut microbiota composition. *Obesity* 20(5):1082–1087
- Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M, Fernandez-Capetillo O (2009) A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. *Nat Genet* 41(8):891–898
- Nagpal R, Mainali R, Ahmadi S, Wang S, Singh R, Kavanagh K, Yadav H (2018) Gut microbiome and aging: Physiological and mechanistic insights. *Nutr Healthy Aging* 4(4):267–285
- Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS (2008) Probiotic administration alters the gut flora

- and attenuates colitis in mice administered dextran sodium sulfate. *J Gastroenterol Hepatol* 23(12):1834–1839
- Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, Häslér R (2017) Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. *Gastroenterology* 153(6):1504–1516. e1502
- Nouri M, Bredberg A, Weström B, Lavasani S (2014) Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. *PLoS One* 9(9):e106335
- Nyangale EP, Mottram DS, Gibson GR (2012) Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. *J Proteome Res* 11(12):5573–5585
- O'Callaghan A, Van Sinderen D (2016) Bifidobacteria and their role as members of the human gut microbiota. *Front Microbiol* 7:925
- O'Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, Ruder E (2015) Fat, fibre and cancer risk in African Americans and rural Africans. *Nat Commun* 6(1):1–14
- O'Toole PW, Jeffery IB (2015) Gut microbiota and aging. *Science* 350(6265):1214–1215
- Ochoa-Repáraz J, Kasper LH (2014) Gut microbiome and the risk factors in central nervous system autoimmunity. *FEBS Lett* 588(22):4214–4222
- Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao J-Z, Osawa R (2016) Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol* 16(1):1–12
- Olbe L, Carlsson E, Lindberg P (2003) A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. *Nat Rev Drug Discov* 2(2):132–139
- Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Kasper DL (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* 336(6080):489–493
- Organization, W. H. (2018) WHO report on surveillance of antibiotic consumption: 2016–2018 early implementation
- Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, Franceschi C (2008) Immunosenescence and immunogenetics of human longevity. *Neuroimmunomodulation* 15(4–6):224–240
- Owaga E, Hsieh R-H, Mugendi B, Masuku S, Shih C-K, Chang J-S (2015) Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. *Int J Mol Sci* 16(9):20841–20858
- Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Colombel J-F (2018) Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Gut* 67(3):574–587
- Palmer AK, Jensen MD (2022) Metabolic changes in aging humans: current evidence and therapeutic strategies. *J Clin Invest* 132(16):e158451
- Park CB, Larsson N-G (2011) Mitochondrial DNA mutations in disease and aging. *J Cell Biol* 193(5):809–818
- Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Machiels K (2017) A microbial signature for Crohn's disease. *Gut* 66(5):813–822
- Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Ghensi P (2019) Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. *Cell* 176(3):649–662. e620
- Penedo FJ, Dahn JR (2005) Exercise and well-being: a review of mental and physical health benefits associated with physical activity. *Curr Opin Psychiatry* 18(2):189–193
- Pokusaeva K, Fitzgerald GF, van Sinderen D (2011) Carbohydrate metabolism in Bifidobacteria. *Genes Nutr* 6:285–306
- Powell N, Pantazi E, Pavlidis P, Tsakmaki A, Li K, Yang F, Minns D (2020) Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. *Gut* 69(3):578–590
- Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Yamada T (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464(7285):59–65
- Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y (2022) The gut microbiota in inflammatory bowel disease. *Front Cell Infect Microbiol* 12:733992
- Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shanahan CM (2010) Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* 121(20):2200–2210
- Rajilić-Stojanović M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, De Vos WM (2009) Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol* 11(7):1736–1751
- Ramakrishna B, Gee D, Weiss A, Pannall P, Roberts-Thomson I, Roediger W (1989) Estimation of phenolic conjugation by colonic mucosa. *J Clin Pathol* 42(6):620–623
- Ramakrishna B, Roediger W (1990) Bacterial short chain fatty acids: their role in gastrointestinal disease. *Digest Dis* 8(6):337–345
- Ramakrishna B, Venkataraman S, Mukhopadhyaya A (2006) Tropical malabsorption. *Postgrad Med J* 82(974):779–787
- Ramakrishna BS (2007) The normal bacterial flora of the human intestine and its regulation. *J Clin Gastroenterol* 41:S2–S6
- Ramakrishna BS (2013) Role of the gut microbiota in human nutrition and metabolism. *J Gastroenterol Hepatol* 28:9–17
- Rampelli S, Soverini M, D'Amico F, Barone M, Tavella T, Monti D, Biagi E (2020) Shotgun metagenomics of gut microbiota in humans with up to extreme longevity and the increasing role of xenobiotic degradation. *Msystems* 5(2):e00124-00120
- Razak PA, Richard KJ, Thankachan RP, Hafiz KA, Kumar KN, Sameer K (2014) Geriatric oral health: a review article. *J Int Oral Health* 6(6):110
- Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Bain JR (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* 341(6150):1241214
- Rios-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De Los Reyes-Gavilán CG, Salazar N (2016) Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol* 7:185
- Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One* 7(4):e34938
- Rogier EW, Frantz AL, Bruno ME, Wedlund L, Cohen DA, Stromberg AJ, Kaetzel CS (2014) Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. *Proc Natl Acad Sci* 111(8):3074–3079
- Rogier R, Koenders MI, Abdollahi-Roodsaz S (2015) Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. *J Immunol Res* 2015
- Rosier B, Marsh P, Mira A (2018) Resilience of the oral microbiota in health: mechanisms that prevent dysbiosis. *J Dent Res* 97(4):371–380
- Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Bar N (2018) Environment dominates over host genetics in shaping human gut microbiota. *Nature* 555(7695):210–215
- Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 9(5):313–323
- Russell JB, Diez-Gonzalez F (1997) The effects of fermentation acids on bacterial growth. *Adv Microb Physiol* 39:205–234
- Rutayisire E, Huang K, Liu Y, Tao F (2016) The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review. *BMC Gastroenterol* 16(1):1–12
- Sabater-Molina M, Larqué E, Torrella F, Zamora S (2009) Dietary fructooligosaccharides and potential benefits on health. *J Physiol Biochem* 65:315–328
- Saffrey MJ (2014) Aging of the mammalian gastrointestinal tract: a complex organ system. *Age* 36:1019–1032
- Sakai F, Hosoya T, Ono-Ohmachi A, Ukibe K, Ogawa A, Moriya T, Nakayama Y (2014) *Lactobacillus gasserii* SBT2055 induces TGF- β expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine. *PLoS One* 9(8):e105370
- Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, Smith AM (2021) The role of the microbiome in gastrointestinal inflammation. *Biosci Rep* 41(6)
- Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA (2019) Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Revs Gastroenterol Hepatol* 16(10):605–616
- Sangeetha P, Ramesh M, Prapulla S (2005) Recent trends in the microbial production, analysis and application of fructooligosaccharides. *Trends Food Sci Technol* 16(10):442–457
- Sangwan V, Tomar S, Singh R, Singh A, Ali B (2011) Galactooligosaccharides: novel components of designer foods. *J Food Sci* 76(4):R103–R111
- Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vösa U, Oosting M (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet* 51(4):600–605

- Sarkar A, Harty S, Johnson KVA, Moeller AH, Carmody RN, Lehto SM, Burnet PW (2020) The role of the microbiome in the neurobiology of social behaviour. *Biol Rev* 95(5):1131–1166
- Scheid M, Genaro P, Moreno Y, Pastore G (2014) Freeze-dried powdered yacon: effects of FOS on serum glucose, lipids and intestinal transit in the elderly. *Eur J Nutr* 53:1457–1464
- Scholz-Ahrens KE, Schrezenmeir J (2002) Inulin, oligofructose and mineral metabolism—experimental data and mechanism. *Br J Nutr* 87(S2):S179–S186
- Scholz-Ahrens KE, Schrezenmeir J, r. (2007) Inulin and oligofructose and mineral metabolism: the evidence from animal trials. *J Nutr* 137(11):2513S–2523S
- Schwartz A, Le Blay G, Blaut M (2000) Quantification of different Eubacterium spp. in human fecal samples with species-specific 16S rRNA-targeted oligonucleotide probes. *Appl Environ Microbiol* 66(1):375–382
- Secher T, Kassem S, Benamar M, Bernard J, Boury M, Barreau F, Saoudi A (2017) Oral administration of the probiotic strain *Escherichia coli* Nissle 1917 reduces susceptibility to neuroinflammation and repairs experimental autoimmune encephalomyelitis-induced intestinal barrier dysfunction. *Front Immunol* 8:1096
- Selma-Royo M, García-Mantrana I, Calatayud M, Parra-Llorca A, Martínez-Costa C, Collado MC (2021) Maternal diet during pregnancy and intestinal markers are associated with early gut microbiota. *Eur J Nutr* 60:1429–1442
- Sender R, Fuchs S, Milo R (2016) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. *Cell* 164(3):337–340
- Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM (2010) Aging of the innate immune system. *Curr Opin Immunol* 22(4):507–513
- Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, Goldman RD (2011) The role of nuclear lamin B1 in cell proliferation and senescence. *Genes Dev* 25(24):2579–2593
- Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. *Arthr Res Ther* 4:1–8
- Sivaprakasam S, Prasad PD, Singh N (2016) Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. *Pharmacol Ther* 164:144–151
- Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, Mychalckyj JC (2013) Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. *Science* 339(6119):548–554
- Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ (2016) *Clostridium difficile* infection. *Nat Rev Dis Prim* 2(1):1–20
- Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, Cortier G (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci* 105(43):16731–16736
- Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P (2017) The resilience of the intestinal microbiota influences health and disease. *Nat Rev Microbiol* 15(10):630–638
- Sonnenburg ED, Sonnenburg JL (2019) The ancestral and industrialized gut microbiota and implications for human health. *Nat Rev Microbiol* 17(6):383–390
- Sonnenburg JL, Bäckhed F (2016) Diet–microbiota interactions as moderators of human metabolism. *Nature* 535(7610):56–64
- Sonnenburg JL, Sonnenburg ED (2019) Vulnerability of the industrialized microbiota. *Science* 366(6464):eaaw9255
- Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Muegge BD (2014) Persistent gut microbiota immaturity in malnourished Bangladeshi children. *Nature* 510(7505):417–421
- Suez J, Zmora N, Elinav E (2020) Probiotics in the next-generation sequencing era. *Gut Microbes* 11(1):77–93
- Sullivan Á, Edlund C, Nord CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. *Lancet Infect Dis* 1(2):101–114
- Sun X, He S, Lv C, Sun X, Wang J, Zheng W, Wang D (2017) Analysis of murine and human Treg subsets in inflammatory bowel disease. *Mol Med Rep* 16(3):2893–2898
- Taniguchi H, Tanisawa K, Sun X, Kubo T, Hoshino Y, Hosokawa M, Higuchi M (2018) Effects of short-term endurance exercise on gut microbiota in elderly men. *Physiol Rep* 6(23):e13935
- Torres DP, Gonçalves M, d. P. F., Teixeira, J. A., & Rodrigues, L. R. (2010) Galacto-oligosaccharides: production, properties, applications, and significance as prebiotics. *Compr Rev Food Sci Food Saf* 9(5):438–454
- Tremaroli V, Bäckhed F (2012) Functional interactions between the gut microbiota and host metabolism. *Nature* 489(7415):242–249
- Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Wibom R (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* 429(6990):417–423
- Tropini C, Moss EL, Merrill BD, Ng KM, Higginbottom SK, Casavant EP, Elias JE (2018) Transient osmotic perturbation causes long-term alteration to the gut microbiota. *Cell* 173(7):1742–1754. e1717
- Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Affourtit JP (2009) A core gut microbiome in obese and lean twins. *Nature* 457(7228):480–484
- Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 444(7122):1027–1031
- Vael C, Verhulst SL, Nelen V, Goossens H, Desager KN (2011) Intestinal microflora and body mass index during the first three years of life: an observational study. *Gut Pathogens* 3(1):1–7
- Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Tijssen JG (2013) Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 368(5):407–415
- Vandenplas Y, Carnielli V, Ksiazek J, Luna MS, Migacheva N, Mosselmans J, Wabitsch M (2020) Factors affecting early-life intestinal microbiota development. *Nutrition* 78:110812
- Vazquez M, Alonso J, Dominguez H, Parajo J (2000) Xylooligosaccharides: manufacture and applications. *Trends Food Sci Technol* 11(11):387–393
- Vemuri R, Gundamaraju R, Shastri MD, Shukla SD, Kalpurath K, Ball M, Eri R (2018) Gut microbial changes, interactions, and their implications on human lifecycle: an ageing perspective. *BioMed Res Int* 2018
- Venkatraman A, Ramakrishna B, Shaji R, Kumar NN, Pulimood A, Patra S (2003) Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-κB. *Am J Physiol Gastrointest Liver Physiol* 285(1):G177–G184
- Vich Vila A, Colliv V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Fu J (2020) Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nat Commun* 11(1):362
- Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abera SF (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 390(10100):1211–1259
- Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Oozeer R (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 143(4):913–916
- Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, Gibson GR (2015) Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabolomics in elderly persons. *Br J Nutr* 114(4):586–595
- Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu Rev Genet* 39:359–407
- Wan MLY, Forsythe SJ, El-Nezami H (2019) Probiotics interaction with food-borne pathogens: a potential alternative to antibiotics and future challenges. *Crit Rev Food Sci Nutr* 59(20):3320–3333
- Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, Wang H (2019) Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. *Cell Res* 29(10):787–803
- Wang Y, Kasper LH (2014) The role of microbiome in central nervous system disorders. *Brain Behav Immun* 38:1–12
- WHO (2019) Nutrition for older persons
- Wildner G (2023) Antigenic mimicry—The key to autoimmunity in immune privileged organs. *J Autoimmun* 137:102942
- Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Jansson JK (2009) Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. *Inflamm Bowel Dis* 15(5):653–660
- Wilson M-MG, Morley JE (2003) Invited review: aging and energy balance. *J Appl Physiol* 95(4):1728–1736
- Windey K, De Preter V, Verbeke K (2012) Relevance of protein fermentation to gut health. *Mol Nutr Food Res* 56(1):184–196

- Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S (2004) Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. *Appl Environ Microbiol* 70(10):6113–6122
- Worman HJ (2012) Nuclear lamins and laminopathies. *J Pathol* 226(2):316–325
- Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, Knight R (2011) Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334(6052):105–108
- Xu H, Liu M, Cao J, Li X, Fan D, Xia Y, Zhao H (2019) The dynamic interplay between the gut microbiota and autoimmune diseases. *J Immunol Res* 2019
- Xu J, Lawley B, Wong G, Otal A, Chen L, Ying TJ, Chong Y-S (2020) Ethnic diversity in infant gut microbiota is apparent before the introduction of complementary diets. *Gut Microbes* 11(5):1362–1373
- Yassour M, Vatanen T, Siljander H, Hämäläinen A-M, Härkönen T, Ryhänen SJ, Gevers D (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. *Sci Transl Med* 8(343):343ra381
- Yatsunenok T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Anokhin AP (2012) Human gut microbiome viewed across age and geography. *Nature* 486(7402):222–227
- Young F, Maguire S (2019) Physiology of ageing. *Anaesth Intensive Care Med* 20(12):735–738
- Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL (2014) Oral, capsulized, frozen fecal microbiota transplantation for relapsing *Clostridium difficile* infection. *JAMA* 312(17):1772–1778
- Zhao L, Qiao X, Zhu J, Zhang X, Jiang J, Hao Y, Ren F (2011) Correlations of fecal bacterial communities with age and living region for the elderly living in Bama, Guangxi, China. *J Microbiol* 49:186–192
- Zhou P, Zhou Y, Liu B, Jin Z, Zhuang X, Dai W, Liu Y (2020) Perinatal antibiotic exposure affects the transmission between maternal and neonatal microbiota and is associated with early-onset sepsis. *Msphere* 5(1):e00984-00919
- Zhu Q, Jiang S, Du G (2020) Effects of exercise frequency on the gut microbiota in elderly individuals. *Microbiologyopen* 9(8):e1053
- Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL (2019) Separating host and microbiome contributions to drug pharmacokinetics and toxicity. *Science* 363(6427):eaat9931
- Zmora N, Suez J, Elinav E (2019) You are what you eat: diet, health and the gut microbiota. *Nat Rev Gastroenterol Hepatol* 16(1):35–56
- Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Brik R, B.Z (2018) Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* 174(6):1388–1405. e1321
- Zsálíg D, Berta A, Tóth V, Szabó Z, Simon K, Figler M, Polyák É (2023) A review of the relationship between gut microbiome and obesity. *Appl Sci* 13(1):610

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

